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Summary 
 
Gene therapy is promising for the treatment of many currently incurable diseases by 
delivering or silencing specific genes with pDNA or siRNA, respectively. Clinical trials 
have mostly been conducted with viral or relatively toxic nonviral nucleic acid delivery 
systems. The biopolymer chitosan have the recent years gained interest in nucleic acid 
delivery. However, chitosan lacks the efficiency of many alternative viral-, lipid- and 
polymer-based delivery systems. Hence, this study was initiated to characterize chitosan 
molecular properties favoring efficient delivery of pDNA and siRNA in mammalian 
cells. Chitosans were optimized by investigating a range of chain lengths (MW/DP), 
chain architectures, degrees of N-acetylation (FA) and concentration in the formulations 
(N/P). Promising siRNA-chitosan nanoparticles were investigated for their potential to 
increase the drug delivery in a blood-brain barrier (BBB) model by silencing the drug 
efflux pump P-glycoprotein (P-gp). 
 
Self-branching of fully de-N-acetylated chitosans was investigated as a strategy to 
optimize the delivery efficiency of pDNA-chitosan nanoparticles. Self-branched (SB) and 
self-branched trisaccharide-substituted chitosan oligomers (SBTCO) of different MW 
(molecular weight) were synthesized, characterized and compared to their linear 
counterparts with respect to delivery efficiency, cellular uptake, formulation stability and 
cytotoxicity. While the linear unmodified chitosans failed to mediate efficient pDNA 
delivery in HeLa cells, the self-branching resulted in high transgene expression at the 
optimal combinations of MW and N/P. The most efficient nanoparticles formed with 
SBTCO exhibited a higher colloidal stability of formulation, efficient internalization 
without excessive cell surface binding and low cytotoxicity. 
 
To identify fundamental chitosan molecular properties for efficient gene silencing, 
siRNA-chitosan nanoparticles were prepared from chitosans of various DP (degree of 
polymerization), chain architectures and FA at N/P 10-60. Structure-activity relationships 
were determined by the cellular uptake of siRNA and the knockdown efficiency. 
Additionally, the nanoparticle cytotoxicity was evaluated on the basis of cellular 
metabolic activity and membrane integrity. The results show that the most efficient gene 
silencing was achieved using fully de-N-acetylated chitosans with number average degree 
of polymerization (DPn)>50 and N/P>10. These chitosans mediated efficient siRNA 
delivery at low siRNA concentrations and potent long-term silencing with minimal 
cytotoxicity. 
 
The BBB limits the availability of drugs to therapeutic targets in the central nervous 
system. The barrier is maintained by membrane bound efflux pumps efficiently 
transporting specific xenobiotics back into the blood. The efflux pump P-gp is expressed 
at high levels in brain endothelial cells and has several drug substrates. Consequently, 
siRNA mediated silencing of the P-gp gene is a feasible strategy to improve the brain 
drug delivery. Herein, siRNA-chitosan nanoparticles selected on basis of the structure-
activity optimization were investigated for potential silencing of P-gp in a BBB model 
cell line. The results show that the transfection of rat brain endothelial cells mediated 
effective knockdown of P-gp with subsequent decrease in P-gp substrate efflux. This 
increased the cellular delivery and efficacy of the model drug doxorubicin. 
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1.  Introduction 
1. Introduction 
 
Gene therapy is the concept of transferring genetic material in the form of nucleic acids 
into somatic cells, tissues or whole organs for treating or at least amending disease. 
Instead of the conventional drug-based therapeutic approach to treat clinical symptoms, 
gene therapy offers a possibility to correct the underlying cause of the disease. The 
success of gene therapy relies on efficient nucleic acid delivery to the target cells1. 
However, the lack of efficient and safe delivery systems is currently a major bottleneck in 
the development of this technology2. The delivery systems can be divided as viral- or 
nonviral, where those based on viruses are most efficient but suffer from issues related to 
their production and safety of use2. The nonviral delivery systems are most commonly 
based on various polymers, lipids, liposomes or peptides3. In polymerͲbased nucleic acid 
delivery systems, cationic polymers are employed to form nanoparticles of characteristics 
suitable for cellular internalization2,4. 
 
As a general introduction, this section starts by covering the basic aspects of gene 
therapy. Next follows an introduction to the biopolymer chitosan and an overview of 
polymeric nonviral delivery vehicles. Furthermore, an overview of the biological barriers 
that the nanoparticles must successfully overcome in nucleic acid delivery is presented. 
Finally, the blood-brain barrier is covered due to its relevance in the last part of this 
study. 
 
1.1 Gene therapy  
The cellular delivery of nucleic acids is a relatively old technology emerging from 
genetic engineering experiments with recombinant DNA in the 1970s5. These 
experiments illustrated the possibility of transferring functional genes between different 
species5. The first approved clinical trial aiming to introduce genes in humans started in 
19906 and the promising results emerging from this investigation encouraged further 
research7. Another relevant hallmark is the publishing of the human genome sequence in 
20018. This formed a foundation for the possibility to characterize and indentify genes 
involved in diseases, giving an additional motivation for gene therapy research. 
Combined with the rapidly declining cost and improved output of genomic sequencing9, 
gene therapy can very well be the breakthrough for personalized medicine. 
 
However, as of 2011 and 1,643 approved clinical trials later10, only two commercial 
cancer gene therapy products (Gendicine and Oncorine) are available. The efficacy and 
safety of these viral-based gene medicines is a topic of debate11,12 and currently they are 
only approved for use in China13,14. To overcome the issues preventing this technology to 
reach the clinic, gene therapy is a field of intensive research effort worldwide. The 
enormous interest can be explained by the vast opportunities in treating severe congenital 
and acquired genetic disorders of which many are currently incurable. 
 
The genetic manipulations facilitated by nucleic acid delivery is normally performed with 
plasmid DNA (pDNA) for replacing defective genes or short RNA sequences such as 
small interfering RNA (siRNA) for blocking the expression of harmful genes. 
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1.1.1 pDNA delivery 
The pDNA introduced into cells carries the gene of interest linked to a promoter and 
enhancer ensuring efficient expression15. pDNA delivery has many applications besides 
gene therapy; e.g. as an experimental tool16,17, it can be utilized for industrial production 
of proteins18 and is promising for the development of a new generation vaccines19. 
Several therapeutic targets for pDNA delivery have been addressed in gene therapy, and 
some examples from animal models and clinical studies are given in Table 1-1. 
 
Table 1-1: Selected studies addressing pDNA delivery in animal models and clinical trials. 
In vivo animal models 
Targeted Delivered Delivery Route of Animal Ref.
disease gene system administration model  
Glaucoma BDNF + TrkB Adeno-associated virus Intraocular Rat 20 
Huntington BDNF + GDNF Adeno-associated virus Intracranial Rat 21 
Hemophilia Factor VIII Chitosan (polymer) Oral Mouse 22 
Vaccine Derp2 Chitosan (polymer) Oral Mouse 23 
Colon cancer Apc Lipofectamine (lipid) Oral Mouse 24 
      
In vivo clinical studies 
Targeted Delivered Delivery Route of Clinical Ref.
disease gene system administration phase  
Parkinson GAD Adeno-associated virus Intracranial II* 25 
Cystic fibrosis CFTR DOTAP (liposome) Intranasal I 26 
Bladder cancer Diphtheria toxin PEI (polymer) Intravesical I/II 27 
Cystic fibrosis CFTR PEG-PLL (polymer-peptide) Intranasal II 28 
SCID ADA Retrovirus Ex vivo I/II 6 
ADA: Adenosine deaminase, Apc: Adenomatous polyposis coli, BDNF: Brain-derived 
neurotrophic factor, CFTR: Cystic fibrosis transmembrane conductance regulator, Derp2: Encodes 
the major house dust mite allergen, GAD: Glutamic acid decarboxylase, GDNF: Glial cell-derived 
neurotrophic factor, Intravesical: Delivery directly into the bladder (see Figure 1-6 for an overview 
of the most common administration routes in humans), PEG: Polyethylene glycol, PEI: 
Polyethylenimine, PLL: Poly-l-lysine, SCID: Severe combined immunodeficiency, TrkB: 
Tropomyosin-related kinase B. *Study is terminated. 
 
Expression of the delivered gene depends on successful transport of the pDNA into the 
cellular nucleus where the gene must be processed by the cellular transcription 
machinery. Once transcribed into mRNA, the gene is transported to the cytoplasm and 
binds freely-floating ribosomes possibly directed to the surface of the rough endoplasmic 
reticulum (ER). The ribosomes then translate the mRNA into proteins. If the protein is 
synthesized in the ER, it either remains or is transported to the Golgi network for further 
post-translational modifications crucial for protein functionality. From the Golgi network, 
the protein is delivered to its final destination, either integrated into the plasma membrane 
or secreted extracellularly. If the protein is synthesized in the cytoplasm it usually ends 
up fully functional here or, if carrying appropriate signaling peptides, is transported into 
cellular organelles such as the nucleus or the mitochondria.29 
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1.1.2 siRNA delivery 
RNA-interference (RNAi) is an important regulatory mechanism in cells, involved in the 
regulation of endogenous gene expression by inducing degradation of mRNA30. RNAi is 
suggested to be an evolutionary conserved mechanism as defense against viruses and a 
means to shut off transposon migration30,31. The interest in RNAi was triggered by Nobel 
Prize winning experiments in the late 1990s, demonstrating that introduction of double-
stranded (ds) RNA mediated specific silencing of genes in eukaryotic cells32. A few years 
later, gene silencing induced by synthetic small interfering RNA (siRNA) was 
demonstrated in mammalian cells in vitro33. In 2003, the first successful therapeutic in 
vivo siRNA delivery experiment was performed in mice34, followed by the first clinical 
study initiated in 200435. 
 
RNAi represents a new and potent strategy for post-transcriptional silencing of specific 
genes that can be mediated by delivery of synthetic double-stranded siRNA. RNAi has 
become a well established tool for gene function analysis36 and has shown promising 
therapeutic results37-46. Several therapeutic targets for siRNA delivery have been 
addressed in clinical trials to overcome diseases by gene silencing. Some examples are 
given in Table 1-2. 
 
Table 1-2: Selected studies addressing siRNA delivery and gene silencing in animal models and clinical 
trials. 
In vivo animal models 
Targeted Silenced Delivery Route of Animal Ref.
disease gene system administration model  
Rheumatoid arthritis TNF-Į Chitosan (polymer) Intraperitoneal Mouse 37 
Gut inflammation Cyclin D1 Liposome-based Intravenous Mouse 44 
Cancer VEGF R2 PEI-PEG-RGD (polymer) Subcutaneous Mouse 45 
Influenza Viral capsid PEI (polymer) Retroorbital Mouse 46 
High cholesterol ApoB PLL (peptide) Intravenous Mouse 38 
      
In vivo clinical studies 
Targeted Silenced Delivery Route of Clinical Ref.
disease gene system administration phase  
Cancer RRM2 CDP-PEG-Tf (polymer) Intravenous I 39 
Hepatitis B 4 viral genes Lipid-based Intravenous I* 41 
AMD VEGF Modified naked siRNA Intraocular II* 42 
PC K6a Naked siRNA Topical I 43 
RSV Viral capsid Naked siRNA Intranasal II 40 
AMD: Age-related macular degeneration, ApoB: Apolipoprotein B, CDP: Cyclodextrin based 
polymer, K6a: Keratin 6a, PLL: Poly-l-lysine, Tf: Transferrin, RRM2: Ribonucleotide 
reductase M2, RSV: Respiratory syncytial virus, PC: Pachyonychia congenita, VEGF R2: 
Vascular endothelial growth factor receptor 2. *Study is terminated. 
 
There are several pathways of RNAi culminating in gene silencing30,47,48. An overview of 
the gene silencing mechanisms is shown in Figure 1-1. 
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Figure 1-1: The mechanisms and possible pathways culminating in RNAi. The numbers refer to the details 
in the text. Adapted from Becker et al.29. 
 
RNAi can be artificially induced either by delivering dsRNA (e.g. siRNA) into the 
cytoplasm, or by nuclear delivery of plasmids expressing small hairpin RNA (shRNA) 
which after synthesis is exported to the cytoplasm by the protein exportin 5 for further 
processing into siRNA49. When a cell internalize long dsRNA or express shRNA and 
release it into the cytoplasm, the RNaseIII-type enzyme Dicer cleaves it into siRNA 
fragments (Step 1 in Figure 1-1) of approximately 21 base pairs (bp)50. However, when 
delivering siRNA to cells for gene silencing, this step will not be necessary since the 
nucleotides already are of appropriate size. Delivering siRNA instead of shRNA or longer 
dsRNA is beneficial for avoiding the need of nucleic acid delivery to the nucleus or 
possible activation of the immune receptors sensitive to dsRNA longer than 30 bp51, 
respectively. In the next step (Step 2 in Figure 1-1), the siRNA is loaded into the RNA-
induced silencing complex (RISC)52. Ago2, an enzyme component of RISC, cleaves and 
discards one of the siRNA strands (sense strand) while the other (antisense strand) is 
retained (Step 3 in Figure 1-1)52. If the RNA is perfect or near perfectly complementary 
to the target mRNA, it will follow the post-transcriptional gene silencing pathway (Step 
4a in Figure 1-1)47. The RISC-associated siRNA strand then binds complementary 
mRNA sequences, and the endonuclease region of RISC cleaves the target mRNA at the 
4 
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site between nucleotide 10 and 11 complementary to the antisense strand relative to the 
5ƍ-end (Step 5a in Figure 1-1)52. The target mRNA is then released and further degraded 
by intracellular nucleases53. After cleavage and release, the processive siRNA-RISC 
complex is capable of binding new complementary mRNA in a catalytic fashion48. This 
ultimately results in gene silencing due to the depletion of mRNA available for protein 
synthesis. If the RNA is not fully complementary to the target mRNA (Step 5b in Figure 
1-1) it will mediate translational repression either by binding but not degrading the target 
mRNA, or by non-specific degradation47. 
 
Transcriptional gene silencing (Step 4b in Figure 1-1) only occurs if the siRNA is 
complementary to promoter regions and delivered to the nucleus54. This triggers 
chromatin remodeling and histone modifications, binding of siRNA to the genomic DNA 
and inhibition of the gene expression55. 
 
The endogenous gene regulatory function of RNAi is ensured by microRNAs56. They are 
derived from non-coding hairpin RNA transcribed by the genome, most often imperfectly 
paired with their targeting mRNA56. The microRNAs will not be further discussed in this 
thesis. 
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1.2 Chitosan 
 
1.2.1 Molecular properties 
The polysaccharide chitosan is a cationic linear copolymer of ȕ-1,4 glycosidic bond 
linked N-acetyl-D-glucosamine (GlcNAc; A-unit) and D-glucosamine (GlcN; D-unit). 
The distribution of the two building sugar units in homogeneously deacetylated chitosans 
has been shown to be according to a random distribution57,58. Chitosans are derived from 
water insoluble chitin. The molecular structures of chitin and chitosan are shown in 
Figure 1-2. 
 
 
Figure 1-2: The molecular structures of chitin and chitosan. 
 
The sugar units are in the 4C1 conformation and the ȕ-1,4 linkage gives the chitin and 
chitosan molecules an extended chain conformation where neighboring units are rotated 
180º relative to each other in a similar way as in the cellulose chain. Chitosans can be 
considered as a family of polymers having a fraction of N-acetylated glucosamine units 
(FA) lower than approximately 0.7. There is no generally accepted definition that can 
easily distinguish chitosan and chitin. Chitins and chitosans can vary widely in chain 
lengths, usually expressed as the molecular weight (MW) or the chain length (degree of 
polymerization, DP). As these polysaccharides normally are polydisperse, the MW of a 
sample is an average of the whole distribution of molecular weights. The two most 
common averages are the number-average (Mn) and weight-average (Mw): 
 
 
i i
i
n
i
i
N M
M =
N
¦
¦        Eq. 1 
 
2
i i i i
i i
w
i i
i i
w M N M
M = =
w N
¦ ¦
¦ ¦ iM       Eq. 2 
 
where Ni is the number of molecules with molecular weight Mi and wi is the weight of 
the molecules with molecular weight Mi. In a polydisperse sample Mw>Mn, while in a 
monodisperse sample Mw=Mn. The polydispersity index (PDI) is defined as follows: 
 
 w
n
MPDI=
M
        Eq. 3 
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For a randomly degraded polymer where the undegraded molecules are very long 
compared to the degraded molecules, the PDI will be 2. PDI lower than 2 suggests that a 
fractionation occurred during the production process. On the other hand, a PDI higher 
than 2 possibly indicates a mixing of samples with different molecular weights. A 
convenient method to determine the MW and size distribution of chitins and chitosans is 
size exclusion chromatography (SEC) combined with detectors determining the 
concentration and MW of the fractionated samples. When the molecular weights are 
easured, the chitosan DP is determined by dividing the polymer MW by the 
physiological pH . Chitosan is a weak polybase with an intrinsic pKa of 
pproximately 6.566, making the molecule only slightly positively charged at pH values 
 number of biomedical applications, e.g. in 
ucleic acid delivery, drug delivery67 , as a drug absorption enhancer71, 
, 
imer substituted chitosan oligomers (SBTCO) , respectively. The syntheses of the 
different chitosan molecular architectures are illustrated in Figure 1-3. 
 
m
proportional weight of the GlcN and GlcNAc monomers.  
 
Chitin occurs mainly in the exo-skeleton of crustaceans and insects and is one of the most 
abundant biopolymers in nature59. Chitosan, in contrast, is much less abundant and occurs 
as a component in the cell wall of certain fungi60-62. The main commercial source of 
chitosan is from shellfish waste, where chitin is isolated by chemical extractions, before 
chitosan is obtained by alkaline de-N-acetylation59. Acidic de-N-acetylation results in 
severe degradation of the chain and is therefore not feasible63. The chitosan chain is quite 
stiff and extended due to the rigid 4C1 sugar units, restricted rotation around glycosidic 
bonds, but also charge repulsion from protonated amines64. Nevertheless, the chitosan 
chain is much less stiff than the double-stranded DNA molecule59. The solubility of 
chitosan at neutral pH-values increases at higher FA values, e.g. high molecular weight 
(HMW) chitosans with a degree of acetylation of around 50% (FA 0.5) is fully soluble 
even at pH 9, while fully de-N-acetylated HMW chitosans are completely insoluble at 
neutral pH65. Thus, fully de-N-acetylated chitosans need to have quite short chain lengths 
to be soluble at 63
a
around 7.2-7.4. 
 
The interest in chitosans has been increasing over the last decade, owing to their 
interesting biological properties, availability, excellent safety profile, biodegradability 
and ease of modification. Chitosan is used in a
-70n
immunoadjuvant72 and in wound dressings73.  
 
1.2.2 Self-branching and substitution of linear chitosans 
Several approaches for structural manipulations of chitosan have been developed at the 
Dept. of Biotechnology (NTNU) the recent years74-76. This includes the production of 
fully de-N-acetylated chitosan oligomers of conventional linear structure (LIN)75 and the 
preparation  of chitosans with  self-branched molecular architectures (SB)74. In addition
LIN and SB derivatives substituted with the trisaccharide 2-acetamido-2-deoxy-D-
glucopyranosyl-ȕ-(1-4)-2-acetamido-2-deoxy-D-glucopyranosyl-ȕ-(1-4)-2,5-anhydro-D-
mannofuranose (AAM)76 have resulted in trimer substituted (TCO)76 and self-branched 
77tr
7 
1. Introduction 
 
Figure 1-3: Overview of structure manipulations and synthesis of chitosans for nucleic acid delivery. 
 
Briefly, the LIN chitosans are prepared by nitrous acid depolymerization and reduction of 
a HMW fully de-N-acetylated chitosan75. SB chitosans are prepared by omitting the 
reduction step after depolymerization, and incubated under selective reduction 
conditions74. The TCO and SBTCO are obtained by reductive N-alkylation with AAM of 
LIN and SB, respectively75. 
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1.3 Polymer based nonviral nucleic acid delivery 
Naked nucleic acids are unable to penetrate intact cellular membranes78. In addition, 
nucleotides are prone to degradation by ubiquitous nucleases78. Hence, pDNA and siRNA 
cannot efficiently be transported into cells without the aid of suitable carriers. The ideal 
delivery vehicle for gene therapy is considered to be applied non-invasively. It enters 
only the target cells at specific tissues where it mediates the desired gene regulation for a 
defined length of time, and importantly, without toxic effects79.  
 
Gene therapy was originally performed by viral delivery of nucleic acids, utilizing the 
ability of viruses to efficiently infect cells80. Viral mediated gene delivery and silencing 
are both normally dependent on the nucleic acids to reach the nucleus since viral RNAi is 
mediated by the expression of shRNA. The most commonly used viral delivery systems 
have been based on retroviruses and adenoviruses81. The adenovirus efficiently delivers 
nucleic acids to the nucleus but has high inflammatory potential and often mediates short 
duration of transgene expression81. The retrovirus on the other hand integrates its genome 
into the host genome ensuring stable expression, but this might also induce 
oncogenesis81. Despite delivering nucleic acids very efficiently, the size of viral capsids 
limits the length of the nucleotide sequences that can be transported. In addition, large 
scale production of viruses is difficult and targeting them to specific cell types can be 
challenging82. As a consequence, nonviral nucleic acid delivery systems based on e.g. 
cationic polymers have gained interest.  
 
Cationic polymers spontaneously assemble with DNA/siRNA to form nanoparticles when 
mixed with nucleic acids83-86. This is facilitated by compaction of the nucleic acids via 
electrostatic interactions between the cationic polymer and the anionic phosphate groups 
in the nucleotide backbone. The polycation mediated collapse and compaction of the 
nucleic acid structure is considered to be a two step process86. First, the negative charge 
on the nucleic acid is neutralized by the interacting cations from the polymer, causing 
reduced charge repulsion and decreasing the nucleotide stiffness. Secondly, the resulting 
release of counterions from the polymer and nucleic acids increase the overall entropy 
and drives the complex formation. The resulting nanoparticles can adopt several different 
morphologies such as toroids87, spheroids84,88,89 and rods84,87,89 typically with diameters of 
50-100 nm. This is a significant reduction in size compared to the up to micrometer large 
native pDNA molecules, often several kbp long90. However, the 21 bp siRNA molecule is 
only 2 nm in diameter and 7 nm long, so the nanoparticle formation with siRNA probably 
differs from the process compacting pDNA90 and is expected to rather involve 
interparticle-assembly involving many siRNA molecules. Furthermore, nanoparticle 
assembly with the shorter nucleotides will require cationic polymers of different 
properties due to the lower number of anionic charges per molecule compared to pDNA. 
 
Unfortunately, the polymer based nonviral delivery systems of today have lower delivery 
efficiencies than the viral systems, limiting their current use in vivo91. This emphasizes 
the need to characterize and understand the polymer molecular properties favoring 
efficient nucleic acid delivery for further optimization. 
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1.3.1 Chitosan based nanoparticles 
Chitosan was reported as a gene delivery vehicle for the first time in 1995 by Mumper et 
al.92. This group was also the first to demonstrate in vivo transfection with pDNA-
chitosan nanoparticles83. Numerous studies have proven chitosan to be a promising 
nucleic acid delivery vehicle93, and its use has been increasing the recent years.  
 
Chitosans ability to form nanoparticles with nucleic acids relies on the positive charge 
given by the protonated amino groups of GlcN units, allowing interactions with the 
anionic phosphate groups of nucleotides. The cationic character of chitosan also to a large 
extent determines its aqueous solubility65,77,94. Consequently, the degree of de-N-
acetylation (FA) has major effects on the chitosans nucleic acid delivery efficiency as it 
affects the charge density of the molecule. Moreover, the chitosan length (MW/DP) also 
determines the interactions between the carrier and the nucleic acids. Together with the 
amino/phosphate (i.e. chitosan GlcN/nucleic acid) ratio (N/P), these fundamental 
properties of the nucleic acid-chitosan nanoparticles are important in balancing 
condensation, protection84,87 and intracellular release84,95-97, to ensure efficient nucleic 
acid delivery. The different properties will be presented in more detail in the following 
paragraphs. Since the short siRNA molecules allow for less charge interactions compared 
to the longer pDNA, the required properties for the chitosan carrier molecule in these 
applications differ90,98. 
 
1.3.1.1 Effect of the degree of de-N-acetylation 
The degree of de-N-acetylation largely influences the chitosan charge density and 
solubility65, but also its degradability63,99-101. Previous studies have discovered a positive 
correlation between low FA and efficient nucleic acid delivery84,102. Kiang et al.102 
discovered that chitosans of lower FA mediated better transgene expression in a range of 
different cell lines. Furthermore, FA<0.35 has been shown necessary to mediate stable 
complexes able to transfect cells103. It has also been shown that increasing the FA results 
in increased particle size and lower net charge, followed by decreased gene delivery104. 
Similarly, chitosan mediated siRNA delivery have shown more efficient gene silencing at 
lower FA84. Possible explanations can be that charge dense chitosans interact more 
efficient with the nucleic acids during the assembly, resulting in more condensed and 
stable nanoparticles, well protected from nucleases. In addition, the net positive charge of 
nanoparticles assembled at lower FA is higher104, promoting interactions with the 
negatively charged cell surface. Since the number of charges per molecule of siRNA 
nucleotides is low compared to pDNA, the FA is possibly an even more important 
chitosan molecular parameter in gene silencing applications.  
 
1.3.1.2 Effect of the chain length 
The length of the chitosan chain influences nanoparticle size and stability77,95,105, cellular 
internalization97,106 and determines the ability to release nucleic acids after complex 
formation97,106. A decrease in pDNA-chitosan particle size is observed when decreasing 
the MW of chitosan83. However, if the chitosan MW is too low the particle size will 
increase, indicating poor ability for nucleic acid condensation104. This correlates well 
with the observation that shorter chitosans are less efficient in protecting pDNA due to 
reduced particle stability107. In addition, chain entanglement is less involved in the 
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complex formation if the chitosan is short102. On the other hand, too high MW is known 
to result in very stable nanoparticles unable to release pDNA intracellularly, which leads 
to low transfection efficiency106. This illustrates the need to balance the nanoparticles 
ability to form particles of a size internalizable by cells and to protect but also release the 
nucleic acids. For siRNA delivery, there have been studies showing that higher MW 
chitosans have better gene silencing capability than shorter chitosan oligomers84. This is 
probably linked to the inability of the small siRNA molecules to form stable discrete 
complexes with short chitosans due to low availability of electrostatic interactions84. 
 
1.3.1.3 Effect of the N/P 
The N/P is also found important to balance the nanoparticle stability77,97,102,105,108-111, and 
this parameter affects the particle net surface charge102,108-110. Neutral particles tend to 
aggregate, while positively charged particles repel each other112. In addition, positively 
charged particles bind more efficiently to the anionic cell surfaces104. There is also 
evidence that positive charge helps nanoparticles reach the nucleus by binding to 
microtubules, molecular motor proteins and move along the cytoskeletal network113. It 
has been suggested that higher N/P values results in higher chitosan concentrations in the 
nanoparticles, possibly increasing the osmotic pressure in the endosomes and facilitating 
release to the cytoplasm98. This view is strengthened by another study suggesting that the 
free chitosan in solution promotes lysosomal escape after uptake114. Nevertheless, the N/P 
must be optimized since too low ratios give unstable particles, while too high N/P results 
in very stable particles that cannot dissociate. In general, pDNA delivery seems to depend 
on lower N/P values compared to siRNA delivery84,97.  
 
Several studies have shown that different combinations of FA and MW need different N/P 
values for optimal pDNA delivery95,102,103. Since chitosan solutions are polydisperse, an 
increase in N/P can therefore compensate for a low MW by providing more high MW 
chitosans. While pDNA delivery seems very dependent on optimization for intracellular 
release97, the assembly of nanoparticles for siRNA delivery appears less prone to result in 
too stable particles, and the delivery is successful even at high N/P and MW84. This is 
probably explained by easier dissociation of the small nucleotides compared to the 
several kbp long pDNA with numerous chitosan interactions. 
 
1.3.1.4 Effect of self-branching and substitution 
Generic chitosans usually mediate poor nucleic acid delivery84,102. This is probably a 
consequence of the low charge density of chitosan near physiological pH values, which is 
manifested in the poor physical and colloidal stabilities of the nanoparticles. The 
optimization of FA, chain length and N/P is not always sufficient to achieve efficient 
nucleic acid delivery with chitosan, and some cell lines have proved difficult to transfect 
with pDNA and linear chitosan77,102,115. In order to improve the nucleic acid delivery 
efficiency with chitosans, molecular modifications are necessary.  
 
Trimer substitution of linear chitosans with AAM has been shown to improve the 
colloidal stability of nanoparticles, resulting in increased gene delivery compared to 
unsubstituted chitosans77,97,116. Substitution with short oligosaccharide chains may also be 
used as a tool to control the unpacking of nanoparticles97. Self-branching has been 
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employed as another tailoring tool, and the self-branching of AAM-substituted chitosan 
oligomers have been shown to enhance the pDNA delivery efficiency77. 
 
1.3.1.5 Effect of serum and cell type 
Another major factor affecting the nucleic acid delivery efficiency is the presence of 
serum77,102,117,118. In general, serum promotes interparticle aggregation due to negatively 
charged proteins119 in addition to nucleic acid degradation by nucleases120. But low serum 
content during transfection have actually been shown to increase the efficiency, probably 
due to increased cell activity121. The delivery efficiency is also very dependent on the cell 
type involved77,102,115,116. This is possibly caused by variations in endocytic activity, rate 
of cell division and growth, side-effects from the nanoparticles and enzymatic 
composition of the endosomes. 
 
1.3.1.6 Effect of pH 
The major disadvantage of chitosan in nucleic acid delivery is its poor solubility at 
physiological pH values that results from deprotonation of the primary amino groups of 
GlcN as a consequence of its pKa-value of 6.5. This makes the charge density of chitosan 
very pH dependent around physiological pH-values. Several studies have shown that 
optimal gene delivery is obtained between pH 6.5 and 7.0, and the efficiency rapidly 
declines at higher pH due to the release of pDNA from the chitosans77,95,121. In addition, 
the interactions between chitosan and siRNA have been shown to decrease at increasing 
pH, where the interactions were negligible at neutral or high pH122. 
 
1.3.2 Other chitosan based delivery systems 
Many approaches have been undertaken in order to increase the performance of nucleic 
acid-chitosan nanoparticles. Some interesting strategies investigated in the literature are 
presented in this section. 
 
1.3.2.1 Conjugation with receptor ligands 
Targeting of chitosan based nanoparticles for improved nucleic acid delivery has been 
carried out by conjugations with a number of receptor specific ligands. Galactose ligands 
have been used to target lectin receptors on hepatocytes115,123,124. The asialoglycoprotein 
receptors, expressed at high levels on hepatocytes125, recognize galactose and could prove 
useful in gene therapy for treating liver diseases. Transferrin receptors are responsible for 
the iron uptake in mammalian cells and are expressed at high levels in most cancer 
cells126. Thus, transferrin ligands have been conjugated to chitosan and were shown to 
increase the pDNA delivery efficiency in e.g. HEK293 and HeLa cells127. Several cells of 
the immune system express high levels of mannose receptors128, and mannose ligands 
have successfully targeted and improved the gene delivery to macrophages using chitosan 
delivery vehicles129. In addition, gene delivery using chitosans with folate ligands have 
improved the transfection efficiency130,131. Folate receptors are overexpressed in many 
human cancers but is absent in most normal tissues132, so folate ligands appears to be a 
potential utility for targeted nucleic acid delivery. To improve siRNA delivery, chitosans 
have been conjugated with RGD peptides targeting integrins in vitro and in vivo tumor 
vasculature133. 
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1.3.2.2 Hydrophilic modifications 
Hydrophilic chitosan derivatives have been made to increase the solubility and decrease 
the pH sensitivity of nucleic acid-chitosan nanoparticles. To increase the charge density 
at physiological pH values, chitosan have been quaternized by trimethylation of the 
amino groups of GlcN134-137. However, a high charge density will also lead to excessive 
unspecific binding and increased interactions with negatively charged extracellular or 
cellular components, such as endogenous intracellular proteins. Hence, the quaternization 
of chitosan has been shown to increase their toxicity135. Furthermore, increasing the 
charge density of chitosan leads to stronger interactions with the nucleic acids and may 
prevent intracellular dissociation due to high nanoparticle stability, as previously 
described. Chitosan nanoparticle stabilization has also been performed with polyethylene 
glycol (PEG) for improved in vitro and in vivo nucleic acid delivery138-142. The 
PEGylation increases the chitosan solubility at physiological pH. Furthermore, it reduces 
the sequestration by the opsonizing immune cells and prevents aggregation with serum 
proteins, thereby elongating the plasma circulation time of nanoparticles. 
 
1.3.2.3 Hydrophobic modifications 
Hydrophobic modifications of polymeric nucleic acid carriers can increase the adsorption 
on cell surfaces and cell uptake143. Introducing hydrophobic units is also thought to assist 
dissociation of the nanoparticles and facilitate nucleic acid release due to a decreased 
occurrence of ionic interactions98. The hydrophobic modification of glycol chitosan with 
5ȕ-cholanic acid has been performed to enhance the uptake and delivery of plasmids, and 
was shown to improve the transfection efficiency in vitro and in vivo144. Deoxycholic 
acid-modified chitosans have also been developed with the aim to increase cell 
membrane-carrier interactions and destabilization of the cell membranes for enhanced 
endosomal release145. The modification with deoxycholic acid was shown to improve the 
transfection efficiency in the presence of serum, and enhanced the nanoparticle 
condensation and protection of pDNA from nucleases145. Another strategy to improve the 
release of nanoparticles from endosomes has been to modify chitosan with stearic acid146. 
This approach resulted in efficient protection of pDNA from nuclease degradation and no 
interference with transfection efficiency was detected in the presence of serum146. 
 
1.3.2.4 pH-sensitive modifications 
Improving the endosomal escape of chitosan based nanoparticles has been approached by 
developing pH-sensitive chitosan carriers. This is an interesting strategy, as inefficient 
release of nanoparticles from the endosomes due to the low buffering capacity of 
conventional chitosans is considered to be one of the primary causes of their poor 
transfection efficiency. The grafting of chitosan with polyethylenimine (PEI) has been 
performed to combine the buffering capacity of PEI to promote endosomal release with 
the biocompatibility of chitosan147-149. Further, urocanic acid-grafting of chitosan has 
been performed for a similar purpose150. The proposed mechanism is that the excellent 
buffer capacity of urocanic acid or PEI will lead to osmotic swelling and rupture of 
endosomes as the pH decrease. This is explained by the resulting accumulation of 
chloride counterions after proton influx and protonation of the polymer, and the following 
water influx and endosomal swelling. This is often referred to as the proton sponge 
effect151. Another pH-sensitive approach has been to introduce thiol groups in chitosan, 
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that are able to form reversible disulfide bonds152. The purpose of this modification has 
been to facilitate the intracellular dissociation of the nanoparticles, as the reductive 
environment and decrease in endosomal pH should result in breaking of the disulfide 
bonds and consequently nanoparticle dissociation. This strategy resulted in increased 
release of pDNA from the chitosan nanoparticles with improved transfection efficiency as 
compared to unmodified chitosan controls152. 
 
1.3.2.5 Co-assembly with negatively charged polymers 
Several negatively charged polymers have been incorporated without covalent 
modification in chitosan nucleic acid nanoparticles to increase the water solubility or 
facilitate intracellular dissociation. One example is the inclusion of negatively charged 
poly(Ȗ-glutamic acid) into chitosan-siRNA nanoparticles153. This resulted in enhanced 
uptake and intracellular dissociation, with more rapid onset in addition to increased and 
prolonged duration of knockdown compared to conventional chitosan-siRNA 
nanoparticles153. Another approach was to include the water soluble vitamin thiamine 
pyrophosphate to increase the solubility of the siRNA-chitosan nanoparticles108. This 
resulted in improved knockdown efficiencies at physiological pH and higher N/P values 
compared to the conventional nanoparticles with chitosan only108. 
 
1.3.3 Other polymer based delivery systems 
 
1.3.3.1 Polyethylenimine 
Polyethylenimine (PEI) is arguably the most commonly used polycation in nucleic acid 
delivery and several commercial transfection reagents based on this polycation are 
available. The molecular structure of PEI has been subject to numerous manipulations to 
improve its physiochemical and biological properties and exists both as linear and 
branched structures as shown in Figure 1-4. 
  
Figure 1-4: The chemical structure of linear and branched polyethylenimine (PEI). 
 
PEI is a very efficient nucleic acid delivery vehicle, probably due to its excellent 
buffering capacity151. The buffering capacity is a result of the high density of amino 
groups and the relatively low pKa value151. The proton sponge hypothesis explains that 
PEI, and possibly other polycations, together with its pDNA cargo is efficiently released 
from the endosomes151. Similar as for chitosan the transfection efficiency of PEI depends 
on the size of the polymer. The transfection efficiency has been shown to increase with 
increasing size for pDNA delivery154. However, the toxicity is also shown to increase for 
larger polymer sizes155,156. The degree of branching has also been shown to affect the 
performance of PEI and it has been shown that linear PEI is less efficient in condensing 
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pDNA compared to branched structures157. However, results comparing the transfection 
efficiency of linear and branched PEI in vitro and in vivo have been conflicting158. PEI 
has also been subject to a number of modifications for improved performance aimed for 
in vivo delivery of nucleic acids. Some examples are PEGylation, inclusion of disulfide 
linkages, grafting with less toxic polymers such as chitosan and conjugation with RGD 
peptides or other ligands such as mannose and galactose3. Successful delivery of siRNA 
resulting in knockdown has also been performed with PEI159,160. 
 
1.3.3.2 Poly-l-lysine 
Poly-l-lysine (PLL) is a cationic polypeptide used extensively for in vitro delivery of 
pDNA161. The molecular structure of PLL is shown in Figure 1-5.  
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Figure 1-5: The molecular structure of poly-l-lysine (PLL). 
 
PLL effectively condenses nucleic acids, but the excessive net-positive charge can 
facilitate interactions with serum proteins and complicate their use for in vivo delivery. 
The pKa value of approximately 10 ensures that PLL is fully protonated at physiological 
pH162, and thus the polymer has no buffering capacity to aid in endosomal escape. 
However, modifications such as conjugation with histidine groups with pKa 6 provides 
buffering capacity and can possibly facilitate the delivery of nucleic acids by also 
reducing the electrostatic binding between PLL and the nucleic acid163. Indeed, this 
modification has been shown to promote efficient delivery of both pDNA and siRNA164. 
To ensure effective condensation of PLL and nucleic acids, a minimum PLL chain length 
must be exceeded165. However, the longer the PLL, the more toxic the resulting 
nanoparticles become166. Furthermore, the use of high molecular weight PLL results in 
aggregation and precipitation167. Similar as for chitosan and PEI, the modification of PLL 
such as PEGylation for improved colloidal stability and ligand conjugations with e.g. 
galactose and transferrin have been performed to improve in vivo performance3. 
 
1.3.3.3 Polymethacrylate and cyclodextrin  
In addition to the widely investigated PEI and PLL polymers, two other examples of 
commonly used polymers for nucleic acid delivery are poly[2-(dimethylamino) 
ethyl methacrylate] (PDMAEMA) and cyclodextrin (CD). PDMAEMA shows efficient 
transfection efficiency due to its ability to destabilize endosomes and easily dissociate in 
the cytoplasm168. However, PDMAEMA suffers from cytotoxic effects169 in addition to 
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aggregation if injected into the blood170. Interestingly, the efficient release of 
PDMAEMA nanoparticles from endosomes appears not to be explainable by the proton 
sponge hypothesis, indicating that also other mechanisms are responsible for the 
endosomal release of nanoparticles based on cationic polymers171. CD has a transfection 
efficiency comparable to PEI172 and the cytotoxic properties of this polymer can be 
reduced by modification of the molecular structure3. Similar as for most cationic 
polymers, CD nanoparticles aggregates at ionic strengths comparable to in vivo 
conditions3. However, modifications improving the colloidal stability are possible, and a 
multicomponent CD based siRNA delivery system have successfully been applied to 
hibit tumor growth in mice173. 
ave been developed. Some examples of such delivery system are presented in 
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1.3.4 Other nonviral delivery systems 
Several nucleic acid delivery systems based on other components rather than cationic 
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1.4 Barriers for cellular delivery of nanoparticles 
The first step in nucleic acid delivery is to assemble stable nanoparticles of appropriate 
size. For successful delivery the particles need to overcome several extra- and 
intracellular barriers. In addition, they must dissociate intracellularly to mediate RNAi or 
gene expression. Nanoparticles may be introduced to target cells in therapeutic 
applications ex vivo179 or in vivo180. Ex vivo delivery is performed by harvesting the target 
cells from the patient and adding the nanoparticles in vitro before the cells are implanted 
back. In vivo administration of nanoparticles in humans as shown in Figure 1-6, 
commonly occurs at local sites such as topical, intranasal, intraocular and oral, or 
systemically by intravenous injection into the blood stream. In animal experiments 
intraperitoneal and intratumoral delivery, and delivery into the central nervous system is 
commonly performed181. 
  
                      
Figure 1-6: The most common routes of nanoparticle administration in humans. Adapted from Yildirimer 
et al.182. 
 
Several anatomical barriers limit the availability to the target cells. The extracellular 
barriers encountered by the nanoparticles depend on the route of administration. For 
example, ocular and topical deliveries circumvent the blood circulation and thus the need 
for the nanoparticles to migrate across endothelial cells and extracellular matrix. Similar, 
intranasal delivery can be an efficient method to reach target cells in the lungs and this 
has previously been shown to be an efficient delivery route for chitosan nanoparticles110. 
However, several barriers are independent on the means of administration, e.g. those 
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encountered at the target cell surface and intracellular. In this section, the barriers 
encountered by intravenously administered nanoparticles are covered. 
 
As illustrated in Figure 1-7 (Step 1), immediately after systemic administration the first 
extracellular barriers are encountered. 
 
 
Figure 1-7: Barriers encountered after systemic administration of nanoparticles for gene therapy. The 
numbers refer to the detail in the text. Adapted from Whitehead et al.180. 
 
Nucleic acids are prone to degradation by nucleases located in the blood, extracellular 
matrix (ECM) and intracellular82,90,180. In addition, phagocytes and macrophages in the 
blood, ECM180 or in tissues82 can efficiently remove injected nanoparticles. The 
nanoparticles can potentially stimulate the immune system resulting in activation of the 
complement system and clearance183. Intravenously administered nanoparticles can also 
be sequestered and lost by electrostatic interactions with serum proteins119,120, which 
facilitates capture and clearance by phagocytosis184. Naked nucleic acids are rapidly 
cleared from the circulation and siRNA molecules are assumed to be freely excreted 
through the kidneys due to the small molecular size91. As a consequence, naked 
unmodified pDNA and siRNA have a half-life of less than 5 minutes in serum after 
systemic administration185,120. 
 
18 
1.  Introduction 
To enter the ECM, intravenously administered nanoparticles must first penetrate the 
endothelium (Step 2 in Figure 1-7). This can be achieved by the enhanced permeability 
and retention effect in tumors, but is more challenging in intact microvasculature90,180. As 
discussed earlier, directing the nanoparticles to target tissues or cells can be mediated by 
conjugating them with receptor specific ligands. Once inside the ECM, the nanoparticles 
need to avoid resident macrophages and interactions with matrix components that prevent 
them from reaching the target cell180. The ECM largely consists of collagen proteins, 
glycosaminoglycans and proteoglycans186. Together, the ECM components form an 
overall negatively charged matrix, potentially immobilizing the transport or disrupting the 
positively charged nanoparticles186.  
 
After the nanoparticles successfully escapes the ECM and reach the target cell (Step 3 in 
Figure 1-7), they will bind to the cell via electrostatic interactions between the cationic 
particle and the anionic cell surface leading to non-specific adsorptive endocytosis, e.g. 
endocytosis, phagocytosis or pinocytosis187. Alternatively, a targeting approach mediated 
by ligands targeting cellular receptors results in clathrin mediated endocytosis187. Naked 
nucleic acids are unable to cross cellular plasma membranes by themselves due to the 
negative charge repulsion from the phosphodiester backbone and the anionic cell surface. 
In addition, the passive transport across the lipid bilayer is size restricted91. 
 
After the nanoparticles have been internalized (Step 4 in Figure 1-7) their intracellular  
processing pathway depends on the mode of uptake187. However, independent on the 
uptake mechanism, the nanoparticles normally end up in endosomes where a gradual 
decrease in pH occurs with a possible subsequent fusion with lysosomes containing 
degrading enzymes188. Hence, the nucleic acids need to escape the endo/lysosomes and 
reach the cytoplasm, either as intact nanoparticles or in naked form after dissociation 
(Step 5 in Figure 1-7). Since lysosomes contain nucleases, the nucleic acids must be 
protected or escape the endosomes before they develop into lysosomes. 
 
When the nanoparticles have dissociated and siRNA is released into the cytoplasm the 
transport ends as the target mRNA resides in this cellular compartment (Step 6 in Figure 
1-7). pDNA on the other hand needs to reach the nucleus for transcription (Step 7 in 
Figure 1-7). Naked pDNA has a very low diffusion rate in the cytoplasm189,190, and as 
mentioned earlier, the nuclear delivery of pDNA seems to depend on transport of the 
cationic nanoparticles along the microtubules113.  
 
The nuclear import of pDNA is assumed to mainly occur during mitosis for dividing 
cells191. Hence, the import is more challenging in non-dividing cells as the pDNA in this 
case needs to gain indirect access to the nucleus by active transport90. This can be 
mediated by nuclear localization signal peptide sequences in transcription factors that 
associates with the pDNA in the cytoplasm and directs internalization with the nuclear 
transport system90.  
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1.5 The blood-brain barrier 
The blood-brain barrier (BBB) is a specialized anatomical and physiological barrier 
constituting a major hurdle for the delivery of systemically injected drugs to the central 
nervous system (CNS). Thus, strategies to overcome this challenge are needed to improve 
the treatment of CNS related diseases. In the current study, chitosan-siRNA nanoparticles 
were investigated as a tool to overcome the limitations in brain drug delivery, and the 
BBB is therefore discussed in this section.  
 
Neurons in the CNS maintain vital functions in humans and animals by synaptic 
communication using chemical and electrical signals192. To ensure reliable signaling, a 
stable local ionic microenvironment at the synapses and axons is critical, with no 
fluctuation of neurotransmitters from the peripheral nervous system. In addition, neurons 
are very sensitive to inflammation and have low toxic threshold for many substances, 
even endogenous metabolites192,193. Replacement of dead neurons is an inefficient, 
limited and slow process, so preventing loss of neuronal cells is important194. Thus, to 
ensure a stable microenvironment and protect neurons from microbes and toxins, the 
CNS has an extraordinary barrier for defence192,195.  
 
The BBB is defined by the endothelial cells lining the capillaries196, recognized by their 
restricted transcytosis due to low pinocytotic activity197,198. The paracellular diffusion 
barrier of the BBB is formed by complex tight junctions sealing the transport pathway 
between the endothelial cells199. Consequently, the barrier is only permeable by 
transcellular passive diffusion across the brain endothelial cells of lipophilic molecules 
with a size less than 400 Da, which includes virtually all commonly used CNS drugs200. 
However, specific transporters at the endothelial cell membranes ensure supply of 
important compounds such as nutrients, hormones and antibodies by active receptor-
mediated or non-specific adsorptive transcytosis201. Importantly, gases such as O2 and 
CO2 diffuse freely across the BBB192. 
 
Despite the ability to freely diffuse across the BBB, even small lipophilic molecules enter 
the brain at very low rate192. This is explained by the presence of cellular efflux pumps 
forming a defensive transcellular diffusion barrier192,202. The efflux pumps maintain the 
BBB by efficient excretion of specific lipophilic xenobiotics diffused into or taken up by 
the endothelial cells192,202. Thus, many drugs are transported across the BBB at low 
efficiency196. This is a pharmacokinetic challenge and currently limits the treatment of 
e.g. schizophrenia203, depression204, brain tumors205, HIV206 and epilepsy207. The best 
characterized BBB efflux pump is P-glycoprotein (P-gp), which is also involved in 
several other physiological barriers208-212 and is often responsible for cancer cell 
multidrug resistance213-216. 
 
1.5.1 Anatomy of the blood-brain barrier 
The cellular elements of the BBB are mainly the endothelial cells, astrocyte end-feet and 
pericytes192. In addition, the brain capillary endothelial cells are surrounded by a thick 
basement membrane of laminins, type IV collagen and heparan sulfate proteoglycans217. 
An overview of the BBB is given in Figure 1-8. 
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Figure 1-8: Schematic illustration of the cells and proteins involved in the blood-brain barrier. Adapted 
from reference 218. 
 
The BBB endothelial cells are connected with specialized tight junctional complexes (TJ) 
in addition to conventional cell-cell adherens junctions (AJ)192,201. The TJ is formed by 
several transmembrane proteins efficiently sealing off paracellular transport. The main 
contributors of the TJ are claudin proteins and occludins, and several cytoplasmic 
scaffolding proteins connecting the transmembrane proteins to the intracellular actin 
cytoskeleton. The AJ provides structural integrity and attachment between the endothelial 
cells and are necessary for the formation of TJ. However, the barrier to paracellular 
diffusion appears to be largely due to the TJ, making the brain parenchyma inaccessible 
for polar- and macromolecules without active transport201. The brain endothelial cells are 
recognized by their high density of mitochondria219. This provides the metabolic work 
capacity needed by the efflux pumps to maintain the ionic gradient across the BBB. 
 
Astrocytic end-feet ensheath over 99% of the microvessels surfaces220 and maintain the 
BBB endothelial cell phenotype with TJ and asymmetric (polarized) organization, with 
an apical (in contact with blood) and basolateral (brain tissue) side201,221. Astrocytes are 
also thought to be regulators of the water permeability in the brain201, and is able to 
change blood vessel diameter in both directions220. Together with the pericytes, astrocytes 
are believed important for the BBB respond to changes in the microenvironment via 
complex signaling cascades222. Astrocytes also express several types of efflux transport 
proteins including P-gp196, possibly mediating xenobiotic efflux to the blood via the 
endothelial cells. 
 
The pericytes are embedded in the basement membrane surrounding the endothelial cells. 
They are shown to be involved in the formation of the TJ, reduction of the pinocytosis 
activity, polarization of astrocyte end-feet and the deposition of astrocyte derived 
basement membrane223. In addition, pericyte-endothelial cell interactions are important 
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during the BBB development224. Similar as the astrocytes, the pericytes can regulate 
blood flow by changing the blood vessel diameter222. As undifferentiated stem cells, the 
pericytes function as supporters of the endothelial cells222. However, they can 
differentiate into smooth muscle cells, fibroblasts or macrophages if needed222. 
  
1.5.2 P-glycoprotein 
Passively diffusing lipophilic molecules are actively effluxed from the brain and its 
capillaries by members of the ABC (ATP-binding cassette) transporter family196. The 
ABC transporters are a superfamily of proteins with 48 members grouped into seven sub-
families225. The ABC transporters of greatest significance in the BBB are P-gp, the 
multidrug resistance proteins (MRPs) and the breast cancer resistance proteins 
(BCRP)226. This section will only cover P-gp, due to its relevance in the last part of this 
study. In addition to the presence in the endothelial cells of the BBB, P-gp is also 
expressed in tissues such as the lungs, kidneys, testes and intestines208-212. P-gp is 
expressed at the apical side of the endothelial cell membranes196 where it transports 
substrates from the BBB to the blood. As mentioned earlier, P-gp is also expressed at the 
astrocytic end-feet196. The molecular structure of P-gp is schematically illustrated in 
Figure 1-9. 
 
 
Figure 1-9: A schematic illustration of the P-gp protein structure. Adapted from Löscher et al.196. 
 
P-gp is a 170 kDa protein of 1,280 amino acids divided in four domains227. Two of the 
domains are cytoplasmic and have nucleotide binding domains providing energy for the 
substrate efflux transport. These domains are preceded by a polytopic membrane 
spanning domain composed of six transmembrane helices. The first extracellular loop has 
three glycosylation sites. In humans, there are two types of P-gp encoded by the MDR1 
and MDR2 gene, whereas only the MDR1 encoded variant is involved in BBB drug 
efflux196. In rodents, two P-gp variants are encoded for by the genes mdr1a and mdr1b. 
The substrate specificity is partly overlapping, but their efflux efficiency and tissue 
distribution differs228,229. In rat brain capillaries, only mdr1a is expressed, whereas only 
mdr1b is expressed in the brain parenchyma212,230. 
  
The exact mechanism of P-gp mediated drug efflux is still unknown. Of the suggested 
models providing an explanation for the efflux mechanism, the so-called flippase model 
is currently favored231. This model suggests that the P-gp substrates gain access to the 
core of the transmembrane domains after interacting with the plasma membrane. At the 
cytoplasmic membrane surface, the P-gp protein flips the drug to the outer leaflet where 
the substrate diffuses out of the cellular membrane. The P-gp substrates are primarily 
cationic, lipophilic planar molecules and the flippase model provides an explanation for 
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why P-gp can have such broad spectrum of substrate drugs, since the only requirement is 
membrane association on the inner plasma membrane leaflet. It also provides an 
explanation for why molecules of higher lipophilicity are more easily removed from a P-
gp expressing cell.  
 
Several structurally diverse drugs are P-gp substrates, limiting their efficacy in therapy. 
Some examples of drugs and associated brain diseases where therapy is limited by P-gp 
efflux are given in Table 1-4. 
 
Table 1-4: P-gp substrate drugs involved in the treatment of brain diseases196,201.  
Drug Class Disease 
Daunorubicin 
Doxorubicin 
Athracycline 
Vincristine 
Vinblastine 
Vinca alkaloid 
Paclitaxel 
Docetaxel 
Taxane 
Brain tumors 
 
Phenobarbital Barbiturate 
Phenytoin Hydantoin derivative 
Epilepsy 
Indinavir 
Saquinavir 
Protease inhibitor Brain HIV 
Erythromycin Macrolide antibiotic 
Actinomycin D Polypeptide antibiotic 
Brain infection
Doxepin Tricyclic antidepressant Depression 
Olanzapine Antipsychotic agent Schizophrenia
 
Previous work on strategies to avoid P-gp mediated drug efflux at the BBB includes the 
use of specific inhibitors232 such as verapamil and cyclosporin A233 and altering the gene 
regulation with e.g. cytokines234 or using lipid mediated drug transport to increase the 
cellular uptake235. In addition, repeated injections of naked siRNA in mice in vivo has 
recently been shown to significantly reduce the expression of P-gp in brain endothelial 
cells236. 
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The overall aim of this study has been to characterize chitosan molecular properties 
favoring efficient pDNA and siRNA delivery in mammalian cells. Furthermore, siRNA-
chitosan nanoparticles were investigated for their potential to improve drug delivery 
across the BBB by silencing the efflux pump P-gp. 
 
This study has resulted in three papers that form the basis of this thesis. The papers are 
attached. The following specific aims have been addressed: 
 
i) Optimize and investigate the effect of self-branching chitosans for improved 
nanoparticle mediated pDNA delivery and transgene expression in HeLa cells (Paper I). 
 
ii) Characterize the chitosan molecular properties favoring efficient siRNA delivery and 
silencing of genes in mammalian cells (Paper II). 
 
iii) Silence P-gp expression in a BBB model using siRNA-chitosan nanoparticles to 
improve the delivery of P-gp substrate drugs to the brain (Paper III). 
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3.1 Paper I 
Alterations of chitosan molecular properties have in numerous studies shown to affect the 
gene delivery efficiency. In this paper, the self-branching of fully de-N-acetylated 
chitosans was investigated as a strategy to optimize the delivery properties of pDNA-
chitosan nanoparticles without compromising the safety profile. SB and SBTCO 
chitosans with a weight average molecular weight (Mw) of 11í71 kDa were synthesized, 
characterized and compared with their linear counterparts with respect to gene delivery 
efficiency, cellular uptake, formulation stability and cytotoxicity. While the linear 
unmodified chitosans failed to transfect HeLa cells, the self-branching resulted in high 
transfection efficiencies. The most efficient chitosan, a SBTCO with a Mw of 30 kDa, 
yielded higher gene expression than the tested commercial transfection reagents. 
Nanoparticles formed with SBTCO chitosans exhibited a higher colloidal stability of 
formulation, efficient internalization without excessive cell surface binding and low 
cytotoxicity. 
 
3.2 Paper II 
Most siRNA delivery studies have been performed with conventional partially N-
acetylated chitosans relying on high N/P and siRNA doses for efficient gene silencing. In 
this study, the purpose was to identify fundamental chitosan molecular properties 
favoring siRNA delivery and efficient gene silencing in mammalian cells. siRNA-
chitosan nanoparticles of N/P 10-60 were prepared from well-defined chitosans of 
various FA, chain lengths and chain architectures. Structure-activity relationships were 
determined by the cellular uptake of siRNA and the knockdown efficiency at mRNA and 
protein levels. Additionally, the nanoparticle cytotoxicity was evaluated on the basis of 
cellular metabolic activity and membrane integrity. The results show that the most 
efficient gene silencing was achieved using fully de-N-acetylated chitosans with number 
average degree of polymerization (DPn)>50 (Mw>16 kDa). These chitosans mediated 
efficient siRNA delivery at low siRNA concentrations and potent long-term silencing of 
both exogenous and endogenous target genes, with minimal cytotoxicity. 
 
3.3 Paper III 
The BBB, composed of tightly organized endothelial cells, limits the availability of drugs 
to therapeutic targets in the CNS. The barrier is maintained by membrane bound efflux 
pumps efficiently transporting specific xenobiotics back into the blood. The efflux pump 
P-gp, expressed at high levels in brain endothelial cells, has several drug substrates. 
Hence, siRNA mediated silencing of the P-gp gene is a possible strategy to improve the 
delivery of drugs to the brain. In this study, siRNA-chitosan nanoparticles selected on 
basis of the results in Paper II were investigated for the potential in silencing P-gp in a 
BBB model. The results show that the transfection of rat brain endothelial cells mediated 
effective knockdown of P-gp with subsequent decrease in P-gp substrate efflux. This 
resulted in increased cellular delivery and efficacy of the model drug doxorubicin. 
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This part summarizes the experimental procedures used in this study. For further details, 
the reader is referred to the attached papers. 
 
4.1 Cell culture 
The HeLa (human cervical cancer) cells were a gift from Prof. Marit Otterlei (Dept. of 
Cancer Research and Molecular Medicine, NTNU). The cells were grown in DMEM 
(Gibco, Invitrogen) supplemented with 1 mM non-essential amino acids (Gibco, 
Invitrogen), 10% FBS (Gibco, Invitrogen) and 1 mM L-glutamine (Sigma). The 
transduced H1299 cell line (human lung carcinoma) stably expressing destabilized EGFP 
(Enhanced Green Fluorescent Protein) was a gift from Prof. Jørgen Kjems (Dept. of 
Molecular Biology, Aarhus University, Denmark). The cells were grown in RPMI 1640 
medium (Sigma) supplemented with 1 mM non-essential amino acids (Gibco, 
Invitrogen), 10% FBS (Gibco, Invitrogen) and 500 ȝg/mL G418 selection antibiotic 
(Sigma). MCF-7 (human breast cancer) cells were provided by Kristin G. Sæterbø (Dept. 
Physics, NTNU) and were grown in MEM (Gibco, Invitrogen) with 1 mM non-essential 
amino acids, 1 mM sodium pyruvate (Gibco, Invitrogen) and 10% FBS. The HUVEC 
(human umbilical vein endothelial) cells were supplied by Lonza and were grown in 
EBM-2 (Lonza) with full supplements (EGM-2 BulletKit, Lonza). The immortalized rat 
endothelial cell line RBE4 was kindly provided by Prof. Tore Syversen (Dept. of 
Neuroscience, NTNU). The cells were grown in alpha MEM supplemented with 10% 
FBS, 300 ȝg/mL G418 selection antibiotic and 1 ng/mL basic fibroblast growth factor 
(Invitrogen). The RBE4 cells were grown on surfaces coated with rat tail type I collagen 
(BD Biosciences). When seeding cells for experiments, the growth medium was 
supplemented with 100 U/mL of penicillin and streptomycin (PEST, Sigma). The cells 
were cultured at 37ºC in a humidified atmosphere with 5% CO2. 
 
4.2 Transfection reagents 
 
4.2.1 Chitosans 
Chitosans were prepared by nitrous acid depolymerization of fully de-N-acetylated 
chitosan (FA<0.002, Mw 146 kDa) as previously described75. To produce the linear 
oligomers, depolymerized chitosan was conventionally reduced by NaBH4, dialyzed and 
lyophilized. Self-branched chitosans were prepared directly after depolymerization by 
omitting the reduction step and incubating the chitosan solution under selective reduction 
conditions (NaCNBH3) for 48 h. The details of the synthesis may be found elsewhere74. 
The glycosylation of chitosans using the trimer 2-acetamido-2-deoxy-D-glucopyranosyl-
ȕ-(1-4)-2-acetamido-2-deoxy-D-glucopyranosyl-ȕ-(1-4)-2,5-anhydro-D-mannofuranose 
(AAM) was carried out as previously described76. For confocal microscopy, the chitosans 
were labeled with an Alexa Fluor 488 succinimidyl ester (Molecular Probes) using a 
molar ratio of 1 dye per 200 GlcN units. 
 
To determine the degree of substitution, the substituted chitosan samples were 
characterized by 1H NMR (Avance DPX 400, Bruker). The weight (Mw) and number 
(Mn) averages of molecular weight and molecular weight distribution were determined by 
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size-exclusion chromatography (SEC) with a refractive index detector (RI, Dawn Optilab 
903, Wyatt Technology) and a multiangle laser light scattering detector (MALLS, Dawn 
DSP, Wyatt Technology). All samples were dissolved in Milli-Q (MQ) deionized water 
(5-7 mg/mL) and filtered through a 0.22 ȝm syringe filter (Millipore). A TSK 3000 
PWXL column (Tosoh Bioscience) was used, and the sample was eluted with 0.2 M 
ammonium acetate (pH 4.5) at a low flow rate of 0.5 mL/min. 
 
The four different structure types of chitosan oligomers are denoted as linear (LIN), self-
branched (SB), trisaccharide-substituted (TCO) and self-branched trisaccharide-
substituted (SBTCO). The number used in the notation is the measured Mw (Paper I) or 
the DPn (Paper II and III). 
 
4.2.2 Commercial 
The lipid-based transfection reagents Lipofectamine 2000 and RNAiMAX were 
purchased from Invitrogen. Exgen 500, a linear PEI (Mw 22 kDa) based transfection 
reagent, was purchased from Fermentas. The reagents were used as described in the 
manufacturer’s protocol. 
 
4.3 Nanoparticle assembly 
Formulations with different N/P values were prepared by a self-assembly method while 
keeping the amount of pDNA or siRNA constant. A solution of nucleic acids was diluted 
with the necessary amount of sterile nuclease free water (5 Prime). Subsequently, the 
required amount of chitosan was added from a sterile filtered solution during vortex 
mixing. The assembled nanoparticles were incubated for 30 min at room temperature 
before transfection. siRNA was normally delivered at 50 or 100 nM, corresponding to 2.5 
or 5.0 pmol per well in a 96 well plate, respectively. While the siRNA was delivered to 
the cells at different concentrations, the pDNA was always delivered at a concentration of 
6.65 ȝg/mL, corresponding to 0.33 ȝg per well. 
 
4.4 Nanoparticle characterization 
 
4.4.1 Dynamic light scattering 
Nanoparticle size determination was performed using dynamic light scattering (DLS) on 
a Zetasizer Nano ZS (Malvern Instruments). Measurements were performed at a 173º 
angle and a temperature of 25ºC when analyzing samples in MQ water. Aggregation 
kinetics were measured by diluting the samples with an equal volume of hypertonic Opti-
MEM and the analysis was performed at 37ºC. The undiluted nucleic acid-chitosan 
nanoparticles were measured at a pDNA/siRNA concentration of 13.3 ȝg/mL. Each 
sample was analyzed in triplicate over a time span of 30 min. The nanoparticle size was 
expressed as the z-average hydrodynamic diameter obtained by a cumulative analysis of 
the correlation function using the viscosity and refractive index of water in the 
calculations. 
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4.4.2 Nanoparticle tracking analysis 
The nanoparticle concentrations were determined using nanoparticle tracking analysis 
(NTA) on a NanoSight LM10 (NanoSight). Measurements were performed in MQ water 
at room temperature using the viscosity of water in the calculations. The siRNA-chitosan 
nanoparticles were measured at a siRNA concentration of 6.65 ȝg/mL. Video capture 
parameters such as the shutter value and recording gain and the analysis parameter 
detection threshold were set manually. The capture duration was set to 60 s and the 
temperature was recorded with a digital thermometer. The sizes measured by NTA were 
similar as those obtained by DLS; sizes of approximately 40-100 nm were observed for 
the siRNA-chitosan nanoparticles.  
 
4.5 Transfection 
Cells were seeded in well plates (Corning) 24 h prior to experiments in densities with 
approximately 90% (pDNA experiments) or 50-75% confluency (siRNA experiments) on 
the day of transfection. The nanoparticles assembled in water were diluted with an equal 
volume of Opti-MEM (Gibco, Invitrogen), supplemented with 270 mM mannitol (Sigma) 
and 20 mM HEPES (Sigma) for adjustment of the osmolarity to 300 mOsm/kg and the 
pH to 7.2. The formulations were not supplemented with FBS or antibiotics. The pH 
value and reduced serum content during transfection was chosen to ensure optimal 
nanoparticle stability while maintaining a physiological environment with limited extent 
of particle aggregation and without deleterious effects on the treated cells. Prior to adding 
the nanoparticles, the cells were washed and briefly incubated with Hank’s balanced salt 
solution (HBSS, Gibco, Invitrogen). Next, the HBSS solution was removed and aliquots 
of nanoparticle formulation were added to each well. The formulations were removed 
after 5 h of incubation and replaced by growth media supplemented with PEST. 
 
4.6 Luminometry 
For analysis of luciferase gene expression post-transfection, cells were washed with PBS 
(Gibco, Invitrogen) and lysed using luciferase lysis buffer (Promega). The luciferase 
activity was measured using a LMax II luminometer (Molecular Devices). Total cell 
protein content was measured using a bicinchoninic acid assay (Pierce) for normalizing 
the luciferase activity to the amount of cells. 
 
4.7 Flow cytometry 
Measurements of cellular delivery or expression of fluorescent molecules were performed 
using a Gallios flow cytometer (Beckman Coulter). At the time of analysis the cells were 
washed in PBS, trypsinized and resuspended in ice-cold PBS supplemented with 5% 
FBS. For each sample, 10,000 gated events were counted and a dot plot of forward scatter 
versus side scatter established a collection gate for cells to exclude cellular debris, dead 
and aggregated cells. The analyzed fluorescent molecules were exited using appropriate 
lasers and emitted light was collected using filters avoiding spectral overlap. 
 
4.8 GAPDH protein activity assay 
The effect of transfection with GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) 
targeting siRNA on the GAPDH protein activity was measured using the commercial 
available KDalert GAPDH assay kit (Ambion) according to the manufacturer’s protocol.  
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4.9 Quantitative real-time RT-PCR 
Knockdown was measured at mRNA levels using the ABI 7500 real-time PCR system 
(Applied Biosystems). The mRNA was harvested, and cDNA was synthesized and 
amplified using the Cells-to-CT kit (Applied Biosystems) as described in the 
manufacturer’s protocol. Primer efficiencies were determined using standard curves. The 
percentage of mRNA expression relative to untreated cells was calculated using the 
comparative Ct method, where the target sample was normalized to the endogenous ȕ-
actin expression. 
 
4.10 Confocal laser scanning microscopy 
Cells were seeded onto 8-chamber microscopic slides (Ibidi) and transfected. At the time 
of analysis, cells were imaged using appropriate lasers and filters for the fluorescent 
molecules that were investigated. The live cells were examined using a LSM 510 (Carl 
Zeiss) confocal laser scanning microscope (CLSM) equipped with a c-Apochromat 
40x/1.2 NA W corr objective. The acquired images had resolutions of 512x512 pixels. 
 
4.11 Toxicity 
 
4.11.1 Metabolic activity 
The effect of transfection on metabolic activity was measured using an Alamar Blue 
assay (Invitrogen). The sample absorbances were measured 4 h after adding the assay 
reagent using a spectrophotometer (Molecular Devices, USA) at 570- and 600-nm. The 
metabolic activity of the cells was evaluated as the reduction in Alamar Blue reagent. 
 
4.11.2 Cellular membrane integrity 
The effects on the cellular membrane integrity from transfection were evaluated using the 
LDH (lactate dehydrogenase) cytotoxicity assay (Cayman), which measures levels of 
cellular cytoplasmic LDH leakage. Measurements of absorbance at 490 nm were 
performed in serum-free medium using a spectrophotometer. 
 
4.12 Rhodamine 123 efflux assay 
A 10 ȝM solution with the P-gp substrate rhodamine 123 (R123, Sigma) diluted in Opti-
MEM was added to the cells. After 45 min of incubation, R123 was removed and 
replaced with growth medium. Two hours after removing the R123, cells were prepared 
for analysis by flow cytometry or CLSM. 
 
4.13 Doxorubicin delivery and efficacy 
One day after transfection the RBE4 cells were added growth medium with 
concentrations of the P-gp substrate, and DNA intercalating agent, doxorubicin 
(Pharmacia) ranging from 0 to 5 ȝM. The cells were incubated with doxorubicin for two 
days before the effect on metabolic activity was measured using the Alamar Blue assay. 
Intracellular doxorubicin delivery was measured two days after transfection by flow 
cytometry or CLSM by incubating the cells in growth medium with 50 M doxorubicin 
for 3 h.  
 
29 
4. Experimental procedures 
30 
4.14 Statistical analysis 
The measured values were collected and given as mean values ± standard deviation (s.d.). 
Statistical differences between the raw data were investigated using the SigmaPlot 11.0 
software package with one-way ANOVA in conjunction with a multiple comparison test 
(Holm-Sidak). 
 
4.15 Summary of analytical techniques 
A summary of the different plasmids and siRNAs used in the study with corresponding 
measured parameters and analytical techniques are given in Table 4-1. 
 
Table 4-1: A summary of the plasmids and siRNA duplexes, measured parameters and analytical methods 
used in the transfection experiments in Paper I-III. 
pDNA Measured parameter post-transfection Analytical method Paper
Cy3 labeled pDNA uptake CLSM I 
GFP encoding GFP expression, number of GFP positive cells FC I 
Luciferase encoding Luciferase expression Luminometry I 
YOYO-1 labeled pDNA uptake, number of YOYO-1 positive cells FC I 
    
siRNA Measured parameter post-transfection Analytical method Paper
Alexa-647 labeled siRNA uptake, number of Alexa-647 positive cells FC, CLSM II, III
EGFP targeting EGFP silencing, number of EGFP positive cells FC, CLSM II 
GAPDH targeting Reduction in mRNA levels and protein activity qRT-PCR, KDalert II, III
NT Non-specific effects, nanoparticle toxicity FC, CLSM, qRT-PCR, KDalert II, III
P-gp targeting Reduction in mRNA levels and protein function qRT-PCR, FC, CLSM III 
Alexa-647: Alexa Fluor 647, CLSM: Confocal laser scanning microscopy, FC: Flow cytometry, 
KDalert: KDalert GAPDH knockdown assay kit,  NT: Non-targeting, qRT-PCR: Quantitative real-time RT-PCR. 
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The initial investigations to be presented in this thesis aimed to characterize chitosan 
molecular and formulation properties, e.g. chain length, chain architecture, FA or N/P 
favoring efficient gene delivery (Paper I) or silencing (Paper II). Nanoparticles selected 
on the basis of the results in Paper II were utilized to silence the drug efflux pump P-gp in 
rat brain endothelial cells, to improve drug delivery across the BBB (Paper III). This 
section highlights the main findings addressing the aims of this study. For further details, 
the reader is referred to the attached papers. 
 
5.1 Self-branching of chitosans for improved pDNA delivery (Paper I) 
Previous studies have illustrated that chitosan mediated pDNA delivery can be optimized 
by balancing parameters affecting the nanoparticle stability and kinetics of intracellular 
dissociation95,97,106. The interest in branched chitosan architectures was initiated by a 
recent study wherein self-branching was used as a tool to increase the colloidal stability 
of nanoparticles formed with AAM-substituted chitosans77. The resulting SBTCO was 
shown to possess higher solubility at pH>7, less aggregation in PBS and it mediated 
higher transgene expression than linear chitosans in HEK293 cells77. Consequently, a 
systematic investigation of the pDNA delivery efficiency of branched chitosans was 
initiated to identify structures with high gene transfer potential and to explain the 
mechanism behind their improved performance. 
 
5.1.1 Transgene expression 
The transfection efficiencies of the self-branched chitosans were found to depend on the 
molecular size (Figure 2 in Paper I). Furthermore, the highest transgene expression in the 
HeLa cells was obtained using formulations with a certain combination of MW and N/P. 
As the MW and N/P determine the physical stability of chitosan based 
nanoparticles95,97,105, the structure-activity relationship observed can be explained in 
terms of a balance between nanoparticle stability and dissociation. The efficient gene 
transfer mediated by nanoparticles with SB or SBTCO with Mw 20-30 kDa indicates that 
these possess optimal stability with protection of the nucleic acids, but also allow 
intracellular dissociation and expression of pDNA. Increasing the MW of the chitosan 
generally lead to more stable particles97,102 that may dissociate too slowly and reside in 
lysosomes106. Also, reducing the N/P have been shown to reduce the stability of pDNA-
chitosan nanoparticles77,97,102,115. Thus, to maintain transgene expression the nanoparticles 
assembled with higher MW chitosans must be destabilized by using a lower N/P and vice 
versa. Nanoparticles falling outside the optimal stability window are likely to possess 
interaction strengths that are too high or too low between the chitosan and pDNA. For the 
AAM-substituted SBTCO chitosans in this study, the range of optimal stability was 
shifted towards higher N/P and higher MW. This was likely a consequence of the trimer 
substitution, which previously has shown to reduce the physical stability of pDNA-
chitosan nanoparticles77,97,116. The rationale behind the impaired stability is probably a 
combination of reduced charge density and steric hindrance of pDNA interactions from 
the AAM-substitutions97. 
 
Previously, it has been indicated that HeLa cells are difficult to transfect with 
conventional linear chitosans102,115. The discovery that self-branched, but not linear, 
chitosans efficiently transfected HeLa cells (Figure 1 in Paper I) was surprising and 
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demonstrated that the molecular architecture of chitosan can be crucial for the pDNA 
delivery efficiency. Thus, direct comparison of nanoparticles based on chitosans derived 
from a linear chitosan with a Mw of 10 kDa was performed to characterize possible 
mechanisms explaining their differing pDNA delivery efficiencies.  
 
The combination of self-branching and substitution of the linear chitosan (SBTCO) 
resulted in high transfection efficiency, exceeding that of the tested commercial 
transfection reagents Exgen and Lipofectamine 2000, as shown from the luciferase 
analysis in Figure 5-1. 
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Figure 5-1: Effect of self-branching and glycosylation on the gene delivery efficiency of chitosan in HeLa 
cells. Self-branched (SB), trisaccharide substituted (TCO), or self-branched trisaccharide substituted 
(SBTCO) chitosans were derived from linear chitosan (LIN) with a Mw of 10 kDa. Luciferase gene 
expression was measured 24 h after transfection using pDNA-chitosan nanoparticles prepared at N/P 3-10. 
The commercial transfection reagents Exgen (EXG) and Lipofectamine 2000 (LFN) were also included. 
SBTCO30 at N/P 10 yielded significantly higher (p<0.05) luciferase gene expression compared with all 
other formulations. The number used in the chitosan notation is the measured Mw. Data represent mean 
values ± s.d., n=4. 
 
5.1.2 Nanoparticle uptake and aggregation kinetics 
The results from flow cytometry analysis of fluorescent labeled pDNA uptake mediated 
by the linear chitosan derived nanoparticles are shown in Figure 5-2. To distinguish 
between internalized and cell surface bound nanoparticles, cells were analyzed before and 
after incubation with trypan blue (TB) used as a quencher of extracellular fluorescence. 
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Figure 5-2: Cellular uptake of pDNA-chitosan nanoparticles in HeLa cells. The measurements are 
presented as the relative amount of internalized pDNA expressed as median fluorescence intensity (FI) of 
the YOYO-1-positive cells. To distinguish between cell surface-bound and internalized nanoparticles, the 
cells were quenched with trypan blue (TB). Blue bars show measurements after TB treatment 
(corresponding to internalized pDNA), whereas white bars show the measurements in the absence of TB 
(surface-bound and internalized pDNA). The cells were analyzed 3 h after transfection. The number used in 
the chitosan notation is the measured Mw. Data represent mean values ± s.d., n=4. 
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Although almost all cells internalized some amount of nanoparticles (Figure 4A in Paper 
I), the flow cytometry analysis revealed large differences in the relative amount of cell 
surface bound (without quenching) and internalized pDNA (quenching with TB) among 
the different formulations. The amount of pDNA delivered intracellularly by LIN 
formulations was considerably lower compared to the other chitosans, and may thus be a 
reason for its poor transfection efficiency. Indeed, most chitosan formulations showing 
poor cellular uptake also mediated poor transfection. Formulations with TCO or SBTCO 
at higher N/P seem to have reduced amounts of internalized pDNA, but higher levels of 
transgene expression. This indicates better intracellular protective capabilities and/or 
dissociation kinetics. Furthermore, cells treated with the commercial transfection reagents 
exhibited very low uptake of pDNA, with levels comparable to the LIN formulations, but 
they showed quite high levels of transgene expression. Therefore, the relationship 
between the amount of internalized pDNA and the amount of transgene produced seems 
to be strongly dependent on the delivery system. This indicates that the tested commercial 
reagents based on PEI and cationic lipids mediate more efficient intracellular processing 
of the internalized pDNA, which has also been suggested elsewhere237-239. 
 
The differences in transfection efficiency of the chitosans cannot solely be explained by 
relative differences in the cellular uptake levels of the nanoparticles, as some of the 
formulations mediated similar uptake but different transgene expression. The lack of 
transgene expression using the linear chitosans may be related to poor uptake or poor 
intracellular trafficking. As reported previously, the nanoparticles of LIN, TCO and 
SBTCO possessed similar sizes and properties77,89. However, the nanoparticles of TCO 
and SBTCO have been shown to be less prone to aggregation at physiological pH values 
in PBS77. Despite aggregating, the linear chitosans have previously shown to mediate 
high pDNA uptake levels and to transfect HEK293 cells95,97. This illustrates cell line-
specific differences related to the uptake and cellular processing of the different particles, 
as previously reported for pDNA-PEI nanoparticles240. HeLa cells may be unable to take 
up larger aggregates or alternatively, different endocytic mechanisms may be involved in 
the uptake and intracellular trafficking of different types of nanoparticles. These 
differences may also be due to a different occurrence of nucleases or chitosan-degrading 
enzymes in the endosomes, making molecular properties affecting the intracellular 
processing more important in certain cell lines. 
 
An extensive binding of LIN and SB nanoparticles to the cell surface was observed in the 
nanoparticle uptake experiments as shown in Figure 5-2. This binding seemed to increase 
with the N/P and was accompanied by a decreasing amount of internalized pDNA. This 
may be a consequence of the increasing amounts of free chitosan in the formulations, 
which competes for cell surface binding via electrostatic interactions. It has previously 
been shown that at N/P 10, 50–70% of the chitosan is unbound to pDNA89. Despite 
possibly reducing the uptake of pDNA-chitosan nanoparticles, the occurrence of free 
chitosan appears to be important for efficient transfection84,96,114. This has been linked to 
facilitation of particle release from the lysosomes114. Regarding in vivo applications of 
the pDNA-chitosan nanoparticles, the need for unbound chitosan to obtain efficient 
transfection can be difficult to fulfill as the free fraction may not follow the particles e.g. 
in the blood stream. 
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The dynamic light scattering analysis of the formulations performed at transfection 
conditions, quantitatively confirmed the severe aggregation of nanoparticles based on 
LIN and SB chitosans, as shown in Figure 5-3A. 
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Figure 5-3: Aggregation of pDNA-chitosan nanoparticles. A) Aggregation of nanoparticles formed with 
unsubstituted chitosans LIN10 and SB30 at N/P 3-10. B) Aggregation of nanoparticles formed with the 
substituted chitosans TCO10 and SBTCO30 at N/P 5-30. The z-average hydrodynamic diameter of the 
particles was measured after diluting the samples with an equal volume of CO2-saturated hypertonic Opti-
MEM to obtain isotonic formulations with a pH of 7.2 and an osmolarity of 300 mOsm/kg. Data represent 
mean values ± s.d., n=3. C) Representative CLSM images of HeLa cells incubated for 2 h with 
nanoparticles of a) LIN10, b) SB30, or c) SBTCO30 at N/P 5. The chitosans were labeled with Alexa Fluor 
488 (green), pDNA was labeled with YOYO-1 (red), and the cellular plasma membrane was stained with 
CellMask (blue). The number used in the chitosan notation is the measured Mw. The bar size is 20 ȝm. 
 
Apparently, the aggregating formulations made from unsubstituted chitosans (LIN and 
SB) sediment on and bind to cell surfaces, as also confirmed by the CLSM imaging as 
shown in Figure 5-3C. In contrast, as shown in Figure 5-3B and C, the nanoparticles 
based on SBTCO with increased colloidal stability were intracellularly located. 
 
The internalization of large aggregates is clearly limited and leads to accumulation of 
aggregated nanoparticles and free chitosan. Interestingly, there was no straightforward 
correlation between the extent of nanoparticle aggregation and the pDNA delivery 
efficiency. The most colloidal stable formulations, SBTCO with Mw 70 kDa at N/P 30 
(Figure 5B in Paper I), and TCO with Mw 10 at N/P 5 (Figure 5-3B), mediated poor 
transfection. On the other hand, the aggregating formulations of SBTCO with Mw 30 kDa 
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were far more efficient (Figure 2 in Paper I). This indicates that colloidal stability of the 
nanoparticles itself does not guarantee successful gene transfer. Possibly, the pDNA 
transported by the colloidal stable particles from TCO with Mw 10 at N/P 5 that showed 
efficient uptake but no transgene expression, was easily degraded by intracellular 
nucleases. In contrast, the stable nanoparticles obtained from SBTCO with Mw 70 at N/P 
30 did possibly not dissociate after internalization. However, a high degree of 
aggregation does seem to correlate with poor transgene expression. For instance, the 
formulations with the most severe aggregation, i.e. LIN with Mw 10 kDa at N/P 3 or 10 
and SB with Mw 30 kDa at N/P 10, failed to transfect the HeLa cells. In contrast, the 
nanoparticles assembled from SB with Mw 30 kDa at N/P 3 and SBTCO with Mw 30 at 
N/P 30 that had lower degrees of aggregation were able to mediate the most efficient 
transfections.  
 
These results illustrate a need for strategies to increase the colloidal stability of pDNA-
chitosan nanoparticles without negatively influencing the physical stability and cellular 
uptake. Such strategies could include grafting of chitosan with PEG, which has been 
previously shown to increase the nanoparticle solubility and prevent aggregation in 
physiological fluids140,141,241. Alternatively, the net positive charge of chitosan based 
nanoparticles could be neutralized with hyaluronic acid142 to reduce the interactions with 
negatively charged components.  
 
5.1.3 Cytotoxicity 
The chitosan-based nanoparticles were based solely on chitosan and no other synthetic 
components, thereby maintaining the high safety profile of chitosan. Analysis of post-
transfection cellular metabolic activity and morphological observation of the nanoparticle 
treated cells confirmed the low toxicity of chitosan (Figure 6 in Paper I), despite the 
changes in molecular architecture from linear to self-branched chains. The result 
correlates well with many previous studies, implying that chitosan is a safe nonviral 
delivery vehicle for potential use in gene therapy in vivo77,105,111,119,139-141. 
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5.2 Molecular optimization of chitosan for siRNA delivery (Paper II) 
Most siRNA delivery studies have been performed with conventional partially N-
acetylated linear chitosans108-110,242. These studies have typically depended on high 
siRNA doses and N/P values to obtain efficient knockdown of the target gene. To 
rationalize the use of chitosans as siRNA delivery vehicles, this study was initiated to 
identify fundamental molecular properties favoring efficient silencing of genes in 
mammalian cells.  
 
5.2.1 Effect of the degree of de-N-acetylation and chain architecture 
The maximum charge density obtained by fully de-N-acetylation of chitosan appears 
crucial to obtain high knockdown efficiencies. This is illustrated by the flow cytometry 
analysis of EGFP fluorescence shown in Figure 5-4A and B. The partially N-acetylated 
chitosan with FA 0.15 and the AAM-substituted SBTCO that contains uncharged GlcNAc 
units, show lower siRNA mediated EGFP knockdown in H1299 cells compared to their 
fully de-N-acetylated counterparts LIN and SB, respectively. 
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Figure 5-4: Effect of chitosan chain architecture and N-acetylation on siRNA delivery and knockdown of 
EGFP in H1299 cells. A) Knockdown of EGFP measured as the median FI or the number of EGFP positive 
cells relative to untreated cells (Un.) 48 h after transfection with anti-EGFP (targeting, T) or non-targeting 
(NT) siRNA. B) Representative CLSM images of a) untreated H1299 cells, 48 h after transfection with b) 
LIN150, c) SB150, d) SBTCO150, e) FA0.15 at N/P 30, or f) RNAiMAX (RiM). The cellular plasma 
membrane was stained with CellMask (blue) and EGFP is indicated with the green colour. The bar size is 
20 ȝm. C) Relative amount of internalized Alexa-647 conjugated siRNA expressed as the median 
fluorescence intensity (FI) of the Alexa-647 positive cells. The cells were analyzed 4 h after transfection.  
The number used in the chitosan notation is the measured DPn. The siRNA was delivered at a concentration 
of 90 nM. Data represent mean values ± s.d., n=3.  
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Results from the flow cytometry analysis of internalized fluorescent siRNA are shown in 
Figure 5-4C. Interestingly, despite lower knockdown efficiencies, the SBTCO and 
partially N-acetylated chitosan showed better cellular uptake of siRNA. This observation 
indicates that the chitosans are able to form stable nanoparticles with siRNA that are 
internalized, but their intracellular protection and/or cellular processing seem less 
efficient than that for the LIN and SB chitosans. This can be compared to the results from 
the substituted chitosan (TCO10 at N/P 5) shown in Figure 5-2 that showed high pDNA 
uptake, however, the transfection efficiency was minimal (Figure 5-1). Possibly, the 
acetylated chitosans release siRNA in the endo/lysosomal compartments, as earlier 
reported for chitosan mediated pDNA delivery106, which results in rapid degradation. 
Indeed, a previous study have shown that siRNA-chitosan nanoparticles are destabilized 
when increasing the FA84, suggesting that the nucleic acids could more easily be degraded 
after uptake. The lower density of protonable amino groups may also render the chitosans 
less efficient in escaping the endosomes, due to reduced buffering capacity and ability to 
mediate endosomal rupture105. 
 
5.2.2 Effect of the chain length of linear chitosans 
Based on the initial experiments showing that fully de-N-acetylated linear chitosans 
mediate efficient siRNA delivery and gene silencing, the effect of the chain length, i.e. 
the size (MW/DP), was investigated as shown in Figure 5-5.  
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Figure 5-5: Effect of chain length and N/P on siRNA uptake and EGFP knockdown efficiency in H1299 
cells, using fully de-N-acetylated linear chitosans. A) Relative amount of internalized Alexa-647 
conjugated siRNA expressed as median FI of the Alexa-647 positive cells. The cells were analyzed 4 h 
after transfection. B) Knockdown of EGFP measured as the median FI or the number of EGFP positive 
cells relative to untreated cells (Un.) 48 h after transfection with anti-EGFP siRNA. The number used in the 
chitosan notation is the measured DPn. The siRNA was delivered at a concentration of 45 nM. Data 
represent mean values ± s.d., n=3. 
 
As shown by flow cytometry analysis of the siRNA uptake and EGFP knockdown, the 
siRNA delivery appears relatively unaffected by the chitosan chain length, particularly 
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for chitosans equal to and above DPn 100 (Mw 35 kDa). When compared to other studies 
using N/P in the range of 50-15084,108-110, the fully de-N-acetylated chitosan nanoparticles 
reach maximum knockdown efficiency at relatively low N/P values such as N/P 10. Only 
the knockdown efficiency of LIN with DPn 50, and partially with DPn 100, increased with 
the N/P, suggesting that some of the chains in the polydisperse sample with average DPn 
50 (PDI 1.52) are able to form stable complexes with siRNA. This is in agreement with 
the results for pDNA delivery where an increase in N/P could compensate for low MW 
(Paper I). The possibility of compensating for the lower DPn of chitosans by increasing 
their N/P is generally not considered an optimal strategy, as higher N/P imply a large 
excess of free chitosans that can bind to the cell surface (as shown for pDNA delivery in 
Figure 5-2), increase the potential for unspecific interactions and complicate the use of 
the nanoparticles in vivo. Therefore, chitosan nanoparticles with low N/P are highly 
beneficial. A plausible explanation for the low N/P needed is that the fully de-N-
acetylated chitosans are able to bind siRNA more tightly, thereby reducing the need for 
excess chitosan. 
 
A significant knockdown of EGFP was achieved at a siRNA concentration as low as 15 
nM (Figure 3 in Paper II), and the maximum gene knockdown was reached at 45 nM 
where the knockdown was found to have duration of at least five days (Figure 4 in Paper 
II). Compared to other studies on polycation mediated siRNA delivery, concentrations in 
the range of 50–200 nM have typically been used to obtain efficient gene silencing, with 
the majority of studies in the upper concentration range of 100-200 nM108-110,159,242,243. 
Similar knockdown efficiencies were also obtained for HEK293 (unpublished data), 
HeLa (unpublished data) and primary HUVEC cells, in addition to MCF-7 cells (Figure 5 
in Paper II) that have previously proved difficult to transfect. This demonstrates that the 
chitosans used in this study could be used as efficient delivery vehicles for siRNA in a 
broad range of cell lines. 
 
5.2.3 Side effects from transfection 
Off-target effects of siRNA, toxicity of the carrier and other non-specific effects have 
repeatedly been lifted as serious concerns in the field of siRNA delivery244-246. Some 
examples of siRNA mediated side effects are induction of the interferon response, 
unspecific intracellular interactions between the material of the delivery vehicle and 
endogenous proteins or nucleic acids, but also possible effects on the global gene 
expression as a consequence of silencing the target gene244,246-248. There is also the 
possibility of unspecific binding of siRNA to mRNA and thereby translational repression 
of genes not intended to be affected by the delivered siRNA. Furthermore, it has been 
suggested that transfection with siRNA can saturate components in the RNAi machinery 
such as RISC, and thereby lead to non-specific effects by perturbing the endogenous 
function of RNAi247. Therefore, in all experiments, appropriate non-targeting (NT) 
siRNA have been used as negative control to distinguish non-sequence specific effects. 
Furthermore, mock transfections with chitosan only were also performed. The analysis of 
EGFP expression presented in Figure 5-6A shows that the delivery of NT siRNA in some 
cases increased the cellular protein levels whereas the naked chitosan in mock 
transfections (M) mediated a decrease in EGFP of approximately 10%. 
  
38 
5. Results and discussion 
In contrast to EGFP, the levels of GAPDH mRNA or protein activity did not seem to be 
affected by delivery of NT siRNA or the mock transfection (Figure 4A in Paper II). This 
indicates that the off-target effects influence random genes and not the global gene 
expression in treated cells. Chitosan released from nanoparticles after their dissociation 
may also possibly bind to EGFP and reduce its turnover rate. The extent of increased 
EGFP seems to be more pronounced for chitosans of mid-range DPn around 100–250. 
Interestingly, as shown by the flow cytometry analysis in Figure 5-6B, mock 
transfections performed at increased chitosan concentrations of 3.5, 35 and 70 ȝg/mL 
(corresponding to N/P 10, 100, and 200) in a time course of 1–3 days show 75–100% 
EGFP compared to the untreated cells. However, the decrease seems to be random with 
respect to the chitosan concentration and is most prominent two days after transfection. 
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Figure 5-6: The effect of chitosan and siRNA-chitosan nanoparticles on EGFP expression. A) The effect 
on EGFP expression from mock transfection (M) or transfection with non-targeting (NT) siRNA. siRNA 
was delivered at a concentration of 45 nM. B) The effect of chitosan concentration (N/P) on EGFP 
expression in H1299 cells measured over three days, using a fully de-N-acetylated linear chitosan with DPn 
200. The effect is measured as the median FI from EGFP relative to untreated cells after mock transfection 
with chitosan only. The number used in the chitosan notation is the measured DPn. Data represent mean 
values ± s.d., n=3. 
 
The siRNA-chitosan nanoparticles showed minimal cytotoxicity as assessed by the 
analysis of metabolic activity and membrane integrity (Figure 6 in Paper II). Similar as 
mentioned earlier for pDNA delivery, the low toxicity of chitosan is in agreement with 
previous studies that recognize different types of siRNA-chitosan nanoparticles as safe 
delivery reagents110,118,242. The optimization of the nucleic acid carrier allows reduction of 
the siRNA dose and N/P, thereby reducing the probability of deleterious side effects.  
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5.3 Chitosan mediated pDNA vs. siRNA delivery (Paper I and II) 
The gene silencing was efficient when using nanoparticles assembled from linear fully-
de-N-acetylated chitosans with DPn>50 and N/P>10. This observation is in contrast to the 
pDNA delivery, where the efficiency of gene transfer had a critical dependency on the 
chitosan molecular size and N/P. A balance have previously been implicated between the 
nanoparticle stability and its ability to undergo intracellular dissociation; the kinetics of 
the intracellular dissociation can be optimized by combining the proper size and N/P 
values97. Since the length of pDNA (typically several kbp) largely exceeds that of siRNA, 
pDNA molecules are able to form multiple inter-chain bridges with chitosan molecules, 
and the electrostatic interactions between pDNA and chitosan are thus much stronger. 
Therefore, by using short chitosan chains (low MW/DP), the interaction strength between 
pDNA and chitosan may be reduced, promoting intracellular dissociation. Short siRNA 
duplexes on the other hand have substantially weaker interaction with chitosan and this 
limits the stability of the nanoparticles. Therefore, above a certain DPn the stability of the 
nanoparticles will not depend on the chitosan chain length. This is in agreement with the 
results presented in this thesis, showing that chitosans below DPn 100 mediate weak 
siRNA uptake and knockdown, probably due to insufficient stability of the nanoparticles. 
This is also in agreement with results reported by Liu et al.84, where a chitosan of 
approximately DPn 50 and FA 0.05 has been shown to form unstable nanoparticles at N/P 
50 mediating poor gene silencing84. This stability hypothesis is supported by observations 
showing that pDNA compared to siRNA seem to form more stable nanoparticles at lower 
N/P values84,97. Increasing the N/P can further increase the stability of the nanoparticles, 
and this can prevent intracellular release. Hence, the pDNA nanoparticles have a lower 
critical N/P compared to siRNA, where no upper limit was detected in the range of N/P 
values tested herein. 
 
Both gene delivery and silencing could be performed with the SB chitosans. The SBTCO 
on the other hand was only able to mediate efficient gene delivery. This is probably 
caused by the reduced charge density and steric hindrance from the AAM-substitution, 
preventing proper association of the chitosan and siRNA, but not the long pDNA 
molecules. However, the SBTCO was able to efficiently silence genes with siRNA in 
HeLa cells (unpublished results). For any conclusion to be drawn from the direct 
comparison of the siRNA and pDNA investigations, the delivery should have been 
performed in the same cell line. 
 
The effects of chitosan chain length, chain architecture, FA and N/P of formulation on 
nucleic acid delivery is summarized in Table 5-1. 
 
Table 5-1: Overview of the effects of chitosan molecular and formulation parameters on the nucleic acid 
delivery. 
Chitosan parameter Optimal for pDNA delivery in HeLa cells Optimal for siRNA delivery in H1299 cells
Size  (MW/DP) Optimal window depending on the chain architecture. Typically Mw 10-40 kDa. 
DPn>50 (Mw>16 kDa) 
Chain architecture TCO, SB and SBTCO perform well LIN and SB perform well 
FA Low FA increases the efficiency Low FA increases the efficiency 
N/P Optimal window depending on the size. Typically N/P 3-30. N/P>10 
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5.4 siRNA-chitosan mediated P-gp silencing in a blood-brain barrier model (Paper III) 
The xenobiotic efflux pump P-gp is expressed in cells at anatomical and physiological 
barriers in mammalian tissues and in malignant cells208-213. Several of the identified P-gp 
substrates are drugs, and thus a considerable research effort has focused on finding ways 
to overcome drug efflux from P-gp expressing cells. Temporarily silencing of the P-gp 
gene by RNAi is a possible way to inhibit the efflux. Previously, this approach has been 
applied to overcome drug resistance in cancer cells by improving the delivery and 
efficacy of chemotherapeutic agents214-216,249. Recently, a preliminary study showed 
reduction in P-gp expression in brain endothelial cells in vivo by repeated hydrodynamic 
injections of naked siRNA intravenously in mice236, but extremely high doses of siRNA 
were used in this study. The delivery of siRNA with nanoparticles may represent a more 
rational approach as the nanoparticles will protect the siRNA from degradation and 
facilitate the uptake, thereby allowing the use of lower doses. 
 
5.4.1 P-gp silencing in rat brain endothelial cells 
A fully de-N-acetylated linear chitosan with a DPn of approximately 400 was selected as 
siRNA delivery vehicle on the basis of the results presented in Paper II. This chitosan 
mediated efficient uptake of siRNA into the RBE4 cells (Figure 1 in Paper III). As shown 
in Figure 5-7, the delivery of anti-P-gp siRNA resulted in efficient silencing of the P-gp 
expression with a reduction in mRNA levels of approximately 80% compared to the 
untreated cells.  
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Figure 5-7: Knockdown of P-gp in RBE4 cells measured at mRNA level by qRT-PCR. The cells were 
transfected with only chitosan (mock, M) or nanoparticles having N/P 30 and P-gp targeting (T) or non-
targeting (NT) siRNA at 100 nM. Cells were also treated with naked siRNA (siRNA). The number used in 
the chitosan notation is the measured DPn. Data represents mean values ± s.d., n=3. 
 
Despite measuring similar concentration of nanoparticles in the formulations (Figure 2 in 
Paper III), the degree of nanoparticle uptake decreased at increasing N/P (Figure 1 in 
Paper III). This indicates that the higher the N/P, the higher is the excess of chitosan in 
the formulation. The excess of unbound chitosan at higher N/P values may inhibit the 
uptake of siRNA by binding to cellular surfaces and preventing the attachment of siRNA-
chitosan nanoparticles. This is similar as earlier mentioned for the pDNA delivery (Figure 
5-2). 
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5.4.2 The effect of P-gp silencing on substrate efflux, drug delivery and efficacy 
Functional activity of the P-gp efflux pump was evaluated using a rhodamine 123 (R123) 
efflux assay (Figure 5 in Paper III). The concentration-response analysis showed a 
considerably lower R123 efflux as the concentration of anti-P-gp siRNA increased from 
10 to 100 nM. A concentration of 45 nM siRNA was shown sufficient for gene silencing 
in a number of cell lines when using fully de-N-acetylated chitosans as delivery vehicles 
(Paper II). However, this may depend on the cell line and the expression of the target 
gene. The P-gp gene is known to be relatively weakly expressed in the RBE4 cell line230 
and this was confirmed by qRT-PCR in this study (unpublished data). Silencing a weakly 
expressed gene could require a higher delivered dose of siRNA before the effect is 
observed due to strong regulation and low availability of target mRNA250,251. This was 
supported by experiments with transfection of C6 cells with even weaker expression of P-
gp compared to the RBE4 cells (unpublished results). In this case, efficient silencing of 
P-gp was not achieved despite promising preliminary GAPDH silencing experiments at 
low siRNA concentrations. Furthermore, the knockdown kinetics (Figure 5 in Paper III) 
show that the reduced P-gp mediated efflux lasted only from one to four days post-
transfection. Such short duration of P-gp knockdown has also been observed in other 
studies with different cancer cell lines, where the protein expression was shown to reach 
its lowest levels one to two days after transfection, and recovered after two to three 
days215,216. A short duration of P-gp knockdown is beneficial since it allows rapid 
reestablishment of the protective function of the BBB after drug therapy. However, it was 
shown that if necessary, it is possible to further reduce the substrate efflux and increase 
the duration of knockdown by repeated transfections (unpublished results). 
 
The reduction in P-gp mediated efflux following successful siRNA transfection improved 
the delivery and considerably increased the efficacy of doxorubicin (Figure 5-8). 
Doxorubicin is a DNA intercalating cytostatic used as a model drug in this study. As 
shown from the metabolic activity assay in Figure 5-8A, cells with silenced P-gp were 
considerably more sensitive to doxorubicin, even at doxorubicin concentrations as low as 
0.5 ȝM. The efficacy of doxorubicin treatment was even higher at 1 ȝM, where up to 
60% reduction in metabolic activity was observed compared to untreated cells with 
normal P-gp expression. 
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Figure 5-8: The effect of P-gp knockdown on doxorubicin efficacy and delivery. A) Drug efficacy 
measured as the reduced metabolic activity after 48 h incubation with doxorubicin in untreated or 
transfected cells. The cells were transfected with LIN400 nanoparticles at N/P 30 with P-gp targeting (T) or 
non-targeting (NT) siRNA concentrations of 50 or 100 nM. Data represents mean values ± s.d., n=4. B) 
Levels of intracellular doxorubicin expressed as the median FI of the cells. Data represents mean values ± 
s.d., n=3. D) Representative CLSM images after transfection with a, b) T or c) NT siRNA or d) untreated 
cells. The cellular plasma membranes in b) were stained with CellMask (blue) and doxorubicin 
fluorescence is indicated with the green color. siRNA was delivered at a concentration of 100 nM. The 
number used in the chitosan notation is the measured DPn. The bar size is 20 ȝm. 
 
As shown by the flow cytometry (Figure 5-8B) and CLSM (Figure 5-8C) analysis, 
doxorubicin was located intracellularly both in transfected and non-transfected cells. 
However, the measured doxorubicin fluorescence intensities were doubled in cells 
transfected with anti-P-gp siRNA as compared to the untreated or NT transfected cells. 
Furthermore, the drug was only able to intercalate with DNA in the nucleus after P-gp 
knockdown. This suggests that P-gp is located both at the cellular membrane (as 
indicated by the R123 experiments) and at the nuclear envelope. Indeed, the expression 
and localization of P-gp in RBE4 cells have previously been confirmed at both sites252. 
Furthermore, doxorubicin has been shown to depend on P-gp silencing for delivery to the 
nucleus of the multi-drug resistant cell line KB-V1214. This illustrates that an improved 
delivery of drugs does not necessarily enhance their efficacy as efflux pumps still can 
prevent them from reaching their final destination, such as the nucleus in the case of 
doxorubicin. Similarly, the dose of drugs needed to obtain a therapeutic window could be 
considerably reduced if a larger fraction reaches its target. This in turn will reduce 
potential deleterious side effects from the drug. 
 
One obvious limitation of using a two-dimensional in vitro model to represent the BBB is 
the lack of a brain interstitium, basal membrane, astrocytes and pericytes. The drugs 
targeting the brain need to cross the layer of endothelial cells and not accumulate inside 
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the capillaries. However, if a drug reaches higher levels in the cytoplasm of the brain 
endothelial cells more of it is expected to enter the brain. Even if a drug is able to cross 
the endothelial cells it can still be prevented from further transport, or even be effluxed 
back to the blood because of efflux pumps in the astrocyte end-feet ensheating the 
capillaries. Thus, the nanoparticles should also penetrate the BBB and transfect cells in 
the brain to even further increase the drug delivery and efficacy. This probably requires 
labeling of the nanoparticles with ligands targeting receptors expressed by brain 
endothelial cells or receptor antibodies facilitating transcytosis. This has previously been 
performed with drug-loaded liposomes labeled with insulin253 and transferrin254 receptor 
antibodies. Receptor-binding nanoparticles also have the benefit of promoting a targeted 
delivery with reduced uptake by irrelevant cells.  
 
Another crucial property of nanoparticles applied in vivo is that they must be stable in the 
blood when administered intravenously. There are several strategies to accomplish this, 
and as mentioned earlier conjugating particles with PEG or shielding the positive charge 
with hyaluronic acid are possible approaches to prevent nanoparticle aggregation. Both 
these approaches were investigated for improved siRNA delivery in this study. However, 
the resulting nanoparticles showing high levels of uptake appeared to have an unbalanced 
stability, either resulting in inefficient intracellular release or alternatively the siRNA 
became degraded due to weak protection from nucleases, resulting in poor gene silencing 
(data not shown). This is similar to the results in Paper I, where the colloidal stable 
pDNA-chitosan nanoparticles failed to mediate efficient transgene expression, even when 
internalized at high levels. Furthermore, the N-acetylated and substituted chitosans in 
Paper II were inefficient in mediating gene silencing despite high levels of siRNA uptake. 
 
Any P-gp substrate can also be a substrate for other drug efflux pumps, e.g. R123 has 
been reported to be transported by Mrp1255 which is also expressed in RBE4 cells230. 
Therefore, even though the P-gp is successfully downregulated, efflux by other pumps 
may still occur. In addition, P-gp is encoded by two different genes in rodents, mdr1a and 
mdr1b, with partly overlapping substrate specificity and efflux efficiency228. In this study 
the focus was on delivering siRNA targeting mdr1a as no effect was measured on R123 
efflux when silencing mdr1b (unpublished data). Despite the possibility of having to deal 
with several different drug efflux pumps to improve the drug delivery, it would be simple 
to assemble nanoparticles with a pooled library of siRNAs targeting several different 
mRNA sequences. 
6. Concluding remarks 
6. Concluding remarks 
 
The work presented in this thesis demonstrates the application of tailored chitosans in 
nucleic acid delivery in vitro. The optimized chitosans showed efficient gene delivery and 
silencing with minimal toxic effects, proving their potential for in vivo applications. The 
major findings in this study as presented in Paper I, II and III were: 
 
- Self-branched chitosans can be optimized for pDNA delivery by adjusting 
parameters determining the physical stability of nanoparticles. The self-branched 
chitosans mediate better pDNA delivery efficiency compared to their linear 
counterparts due to their improved colloidal stability and increased uptake in 
HeLa cells (Paper I). 
 
- Fully de-N-acetylated chitosans of DPn>50 mediate efficient long-term gene 
silencing at low N/P values and siRNA doses (Paper II). 
 
- Silencing the P-gp gene with nanoparticles selected on basis of the results in 
Paper II improved the delivery of P-gp substrates and the efficacy of doxorubicin 
in an in vitro BBB model (Paper III). 
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7. Future studies 
 
The in vitro promising siRNA-chitosan nanoparticles developed herein should be further 
investigated in vivo to realize their potential in gene therapy. In this study, initial in vivo 
experiments aiming for P-gp silencing in rat brain endothelial cells were performed. 
However, these experiments highlighted several challenges that need to be addressed. 
First, the nanoparticles should have a proper targeting molecule, e.g. ligand or antibody, 
directing the particles to endothelial cells in the brain to reduce the dose needed for an 
effect. Furthermore, the particles should be stable in serum but as emphasized they need 
to be able to dissociate and release siRNA intracellularly. Ideally, the nanoparticles 
should mediate an effect after intravenous injection in the tail vein. After successful 
silencing of P-gp, the penetration of P-gp substrate drugs into the brain tissue following 
systemic administration could be evaluated. Also, the effect on drug efficacy after P-gp 
knockdown in vivo should be characterized. 
 
In order to develop stable ligand conjugated nanoparticles for systemic administration, 
further studies need to be performed in vitro to investigate the relationship between 
stability and intracellular trafficking. This can be addressed by using confocal and 
electron microscopy techniques, combined with evaluation of gene silencing efficiency. 
Stabilization of the nanoparticles can possibly be obtained by substitution with a neutral 
oligomer, e.g. PEG, or by shielding the net positive charge using a suitable anionic 
molecule. Furthermore, these approaches can be combined with a layer-by-layer design 
tailoring the nanoparticles with multiple functional layers for optimal performance. After 
the development, promising nanoparticles could be investigated for their accumulation in 
various tissues in vivo after intravenous administration to evaluate the targeting 
specificity. 
 
Since siRNA and pDNA delivery seem to share some common requirements of the 
nucleic acid carrier molecule, strategies mediating efficient siRNA delivery in vivo might 
also very well result in efficient gene delivery with pDNA. By using different ligands, 
these nanoparticles could target different cells in tissues, aiming for the treatment of 
many diseases. 
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ABSTRACT: Chitosan possesses many characteristics of an ideal
gene delivery system. However, the transfection eﬃciency of
conventional chitosans is generally found to be low. In this study,
we investigated the self-branching of chitosans as a strategy to
improve its gene transfer properties without compromising its
safety proﬁle. Self-branched (SB) and self-branched trisacchar-
ide-substituted (SBTCO) chitosans with molecular weights of
11-71 kDawere synthesized, characterized, and compared with
their linear counterparts with respect to transfection eﬃciency,
cellular uptake, formulation stability, and cytotoxicity. Our
studies show that in contrast with unmodiﬁed linear chitosans that were unable to transfect HeLa cells, self-branched chitosans
mediated high transfection eﬃciencies. The most eﬃcient chitosan, SBTCO30, yielded gene expression levels two and ﬁve times
higher than those of Lipofectamine and Exgen, respectively, and was nontoxic to cells. Nanoparticles formed with SBTCO chitosans
exhibited a higher colloidal stability of formulation, eﬃcient internalization without excessive cell surface binding, and low
cytotoxicity.
’ INTRODUCTION
The cellular delivery of nucleic acids is the foundation of gene
therapy and has the potential to treat many currently incurable
diseases. The large size and negative charge of the DNAmolecule
as well as its susceptibility toward degradation are considerable
obstacles to eﬃcient delivery, and numerous viral and nonviral
delivery systems have been investigated. Genetically modiﬁed
viruses have been the carrier of choice in many clinical studies.
However, complications associated with vector safety1-3 as well
as manufacturing and restrictions in therapeutic cargo size4 have
triggered a search for nonviral alternatives. One of the promising
candidates for nonviral gene delivery is the cationic polysacchar-
ide chitosan, a linear copolymer consisting of β-1,4 linked N-
acetyl-D-glucosamine (GlcNAc) and D-glucosamine (GlcN) de-
rived from chitin. The interest in chitosans has been increasing
over the past decade, owing to their availability, excellent safety
proﬁle, biodegradability, ease of modiﬁcation, and interesting
biological properties. The major disadvantage of chitosan is its
poor solubility at physiological pH values that results from the
deprotonation of the primary amine groups of GlcNs, which have
a pKa around 6.5 (25 C, 100 mM NaCl).5,6
Oﬀ-the-shelf chitosans usually mediate poor gene transfer
eﬃciencies. It is often assumed that this is a consequence of the
low charge density of chitosan near physiological pH values,
which is manifested in the poor physical and colloidal stabilities
of DNA-chitosan nanoparticles. One strategy to improve chitosan
properties in gene delivery applications is the tailoring of its
structure. The fraction of acetylated units (FA) and molecular
weight (MW) have been found to be important for the con-
densation of DNA7 and gene transfer eﬃciency.8-10 It has been
recently reported that the eﬃciency of gene delivery using chito-
sans is related to the polyplex stability and kinetics of intracellular
unpacking.11 Our studies also indicate the importance of an
optimal balance between DNA protection and polyplex un-
packing.10
However, the optimization of FA and MW is not always suf-
ﬁcient to achieve eﬃcient transfection with chitosan. Some cell
lines appear to be diﬃcult to transfect with linear chitosan, and
modiﬁcations are necessary to improve the gene transfer.10,12,13
Glycosylation with oligosaccharides such as lactose14 or a
GlcNAc-containing trisaccharide (AAM),15,16 originally applied
to target lectin receptors on hepatocytes, has also been shown to
improve the solubility and reduce the aggregation rate of chitosan
nanoparticles.16 Substitution with short oligosaccharide chains
may also be used as a tool to control the unpacking of poly-
plexes.10 Self-branching has been recently employed as another
tailoring tool, and we showed that the self-branching of glyco-
sylated chitosan oligomers enhanced the transfection.16 How-
ever, only one self-branched chitosan was used in this study, and
the eﬀects of self-branching and glycosylation were not studied
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separately. Self-branched chitosans may be considered to be a
novel and interesting class of chitosans that possess other pro-
perties beyond the conventional linear chains. In a similar man-
ner as that for linear and branched polyethylenimine,17 linear and
branched chitosans may diﬀer in both transfection eﬃciency and
cytotoxicity.
The aim of this study was to investigate the gene delivery
performance of self-branched chitosans compared with their
linear counterparts and to evaluate the impact of self-branching
on the various steps of the gene transfer process. For this pur-
pose, we synthesized a series of self-branched chitosans with and
without oligosaccharide substituents at MWs 11.3-71.0 kDa.
Their transfection eﬃciencies, cellular uptake rates, formulation
stabilities, and cytotoxicities were investigated. This study shows
that in contrast with unmodiﬁed linear chitosans, which are
unable to transfect HeLa cells, self-branched chitosans mediate
eﬃcient nanoparticle uptake and transfection with negligible
cytotoxicity.
’MATERIALS AND METHODS
Plasmid DNA. Reporter plasmids containing a cytomegalovirus
promoter, firefly luciferase or a GFP (green fluorescence protein)
encoding gene were purchased from Aldevron. When appropriate,
plasmid DNA (pDNA) was labeled with the fluorescent dye YOYO-1
(Molecular Probes) using a molar ratio of 1 dye per 100 base pairs. For
confocal microscopy, a noncoding control Cy3-labeled pDNA (Mirus)
was used.
Chitosans. All chitosans used in this study are listed and character-
ized in Table 1.
Chitosans with MWs (weight average,Mw) ranging from 11.3 to 71.0
kDa were prepared by nitrous acid depolymerization of fully de-N-
acetylated chitosan (FA < 0.002,Mw 146 kDa), as previously described.
18
To produce the linear oligomers, depolymerized chitosan was conven-
tionally reduced by NaBH4, dialyzed, and lyophilized. Self-branched
chitosans were prepared directly after depolymerization by omitting the
reduction step and incubating the chitosan solution under selective
reduction conditions (NaCNBH3) for 48 h. The details of the synthesis
may be found elsewhere.19 The glycosylation of chitosans using the
trimer 2-acetamido-2-deoxy-D-glucopyranosyl-β-(1-4)-2-acetamido-2-
deoxy-D-glucopyranosyl-β-(1-4)-2,5-anhydro-D-mannofuranose
(AAM) was carried out as previously described.20
To determine the degree of substitution, the chitosan samples
were characterized by 1H NMR (Avance DPX 400, Bruker). The
weight and number averages of MW and MW distribution were deter-
mined by size-exclusion chromatography (SEC) with a refractive index
detector (RI, Dawn Optilab 903, Wyatt Technology) and a multi-angle
laser light scattering detector (MALLS, DawnDSP,Wyatt Technology).
All samples were dissolved in Milli-Q (MQ) deionized water (5-7 mg/
mL) and ﬁltered through a 0.22 μm syringe ﬁlter (Millipore). A TSK
3000 PWXL column (Tosoh Bioscience) was used, and the sample was
eluted with 0.2 M ammonium acetate (pH 4.5) at a low ﬂow rate of
0.5 mL/min.
The four diﬀerent structure types of chitosan oligomers are denoted
as linear (LIN), self-branched (SB), trisaccharide-substituted (TCO),
and self-branched trisaccharide-substituted (SBTCO). The number
used in the notation is the measured Mw.
For confocal microscopy, the chitosans were labeled with an Alexa
Fluor 488 succinimidyl ester (Molecular Probes) using a molar ratio of 1
dye per 200 glucosamine residues.
Commercial Transfection Reagents. The lipid-based transfec-
tion reagent Lipofectamine 2000 (LFN) was purchased from Invitrogen.
Exgen 500 (EXG), a linear polyethyleneimine (Mw 22 kDa)-based trans-
fection reagent, was purchased from Fermentas. Both reagents were
used as described in the manufacturers’ protocol.
Preparation of pDNA-Chitosan Polyplexes. Formulations
with different amino/phosphate (N/P) ratios were prepared by a self-
assembly method while keeping the amount of pDNA constant (13.3
μg/mL). A stock solution of pDNA (0.5 mg/mL) was diluted with the
necessary amount of sterile MQ water. Subsequently, the required
amount of chitosan was added from a sterile filtered stock solution (2
mg/mL) during vortex mixing (1200 rpm). The assembled complexes
were incubated for 30 min at room temperature before transfection.
Size Analysis. Nanoparticle size determination was performed
using dynamic light scattering (DLS) on a Zetasizer Nano ZS (Malvern
Instruments). Measurements were performed at a 173 angle and a
temperature of 25 Cwhen analyzing samples inMQwater. Aggregation
kinetics was measured by diluting the samples with an equal volume of
hypertonic Opti-MEM (as described in the In Vitro Transfection
section), and the analysis was performed at 37 C. Each sample was
analyzed in triplicate over a time span of 30 min. The polyplex size is
expressed as the z-average hydrodynamic diameter obtained by a
cumulative analysis of the correlation function using the viscosity and
refractive index of water in the calculations.
Cell Culture. The HeLa cells used in these experiments were a
gift from Prof. Marit Otterlei (Dept. of Cancer Research and Molec-
ular Medicine, NTNU). The cells were grown in DMEM (Gibco,
Invitrogen) supplemented with 1 mM nonessential amino acids
(Gibco, Invitrogen), 10%FBS (Gibco, Invitrogen), and 1mM L-glutamine
(Sigma). When seeding cells for experiments, DMEM supplemented with
1% penicillin and streptomycin (PEST, Sigma) was used. The cells were
cultivated at 37 C in a humidified atmosphere with 5% CO2.
Table 1. Characterization of Chitosans Used in the Studya
linear/starting material SB SBTCO
notation Mn Mw PDI Notation Mn Mw PDI Notation Mn Mw PDI d.s.
kDa kDa kDa kDa kDa kDa % AAM
LIN5 4.2 4.7 1.12 SB10 8.3 11.3 1.36 SBTCO10 8.3 11.6 1.40 8.8
LIN8 6.3 8.0 1.28 SB20 12.1 19.8 1.64 SBTCO20 13.0 20.6 1.59 8.4
LIN10 8.5 11.6 1.37 SB30 15.3 27.3 1.78 SBTCO30 15.8 27.1 1.71 8.4
LIN15 10.8 16.4 1.52 SB40 21.3 40.1 1.88 SBTCO40 20.3 38.1 1.88 8.7
LIN25 14.5 24.8 1.71 SB60 28.4 56.6 1.99 SBTCO60 29.8 56.7 1.90 8.5
LIN30 17.6 32.9 1.87 SB70 33.4 67.4 2.02 SBTCO70 33.9 71.0 2.09 8.3
aUnsubstituted chitosans denoted as linear (LIN) have been used as the startingmaterial for self-branched (SB) and self-branched trisaccharide (AAM)-
substituted chitosan oligomers (SBTCO). The weight- and number-averages of molecular weight (Mw, Mn) and molecular weight distribution (PDI)
were analyzed by SEC-MALLS. The degree of AAM-substitution (d.s.) was determined by 1H NMR.
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In Vitro Transfection. HeLa cells were seeded in tissue culture
wells 24 h prior to transfection experiments in densities giving 90%
confluency on the day of transfection. The nanoparticles assembled in
MQ water were diluted with an equal volume of Opti-MEM (Gibco,
Invitrogen), supplemented with 270 mMmannitol (Sigma) and 20 mM
HEPES (Sigma) for adjustment of the osmolarity to 300 mOsm/kg and
pH to 7.2. Prior to the addition of the nanoparticles, the cells were
incubated 20 min in HBSS (Gibco, Invitrogen) at 37 C and 5% CO2.
A volume of 50 μL of polyplexes containing 0.33 μg pDNAwas added to
each well when using 96-well plates. The formulations were removed
after 5 h of incubation and replaced by 200 μL of DMEM supplemented
with PEST. For measurements of luciferase gene expression, the cells
were washed with PBS and lysed using luciferase lysis buffer (Promega).
Luciferase activity (expressed in relative light units, RLU) was measured
using a luminometer (Molecular Devices). Total cell protein content
was measured using the bicinchoninic acid assay (Pierce, IL) for
normalizing the luciferase activity to the amount of cells. GFP expression
was determined using flow cytometry, as described below.
Flow Cytometry. GFP expression and cellular uptake of YOYO-1-
labeled pDNA were measured using a Gallios flow cytometer (Beckman
Coulter). Cells expressing GFP were analyzed 24 h after transfection.
The cells were washed in PBS, trypsinized, resuspended in ice-cold PBS
supplemented with 4% FBS, filtered through 40 μm nylon mesh (BD),
and kept on ice until the time of analysis. The cellular uptake of pDNA
was determined by transfection with YOYO-1-labeled pDNA. After
incubating with polyplexes for 3 h, the cells were washed with PBS and
further incubated with DMEM for 30 min. Afterward, the cells were
washed twice with warm PBS, trypsinized, resuspended in ice-cold PBS
supplemented with 4% FBS, and centrifuged. The supernatant was
removed, and the pellet was resuspended in ice-cold HBSS. These
samples were subsequently analyzed. To estimate the contribution from
extracellularly bound, labeled pDNA, the same samples were also
analyzed after incubation with trypan blue (TB, 400 μg/mL) for 5
min.21 Following TB treatment, the cells were centrifuged, resuspended
in ice-cold HBSS, and analyzed. For each sample, 10 000 gated events
were counted, and a dot plot of forward scatter versus side scatter was
used to establish a collection gate for cells, excluding cellular debris,
dead, and aggregated cells. The GFP- or YOYO-1-positive cells were
excited using a 488 nm laser, and emitted light was collected at FL1 using
a 525/40 band-pass filter. Nontransfected cells were analyzed as negative
controls to set a threshold for fluorescence intensity (FI) above the level
of autofluorescence. The percentage of GFP- or YOYO-1-positive cells
was calculated, and the relative amount of internalized YOYO-1 was
estimated from the median FI of the YOYO-1-positive population.
CLSM and Light Microscopy. HeLa cells were seeded onto
eight-chamber microscopic slides (Ibidi GmbH, Germany) and trans-
fected as described previously. After 2 h of incubation with nanoparti-
cles, the cells to be investigated byCLSMwere treated with 5μg/mL of a
CellMask plasma membrane stain (Invitrogen). Live cells were exam-
ined using a LSM 510 (Carl Zeiss Jena GmbH, Germany) equipped with
a c-Apochromat 40x/1.2 NA W corr objective. Alexa 488-labeled
chitosan, Cy3-labeled pDNA and CellMask were excited using the
488-nm argon, 543-nm HeNe and 633-nm HeNe laser lines, respec-
tively. The emitted light was collected using 500-530 nm band-pass,
565-615 nm band-pass and 650 nm long pass filters. All of the images
had resolutions of 512  512 pixels.
Images for evaluating the eﬀects on cell morphology were captured
with a 10/0.25 objective using a CCD camera (Nikon DS Fi-1)
equipped with a digital image recorder (NikonDigital Sight DS-U2) that
was mounted on a Nikon Eclipse TS100 microscope.
Alamar Blue Assay. The effect of transfection on metabolic
activity was measured using an Alamar blue assay (Invitrogen). A total
of 10 000 cells were seeded in wells and transfected as previously
described. A volume of 10 μL of the Alamar blue assay reagent that was
diluted in 100 μL of growth medium was added to the transfected cells 4
and 24 h post-transfection. The sample absorbances were measured 4 h
after adding the assay reagent using a spectrophotometer (Molecular
Devices) at 570 and 600 nm. The metabolic activity of the cells was
evaluated as a percentage of reduction of the Alamar blue reagent relative
to the nontransfected cells that were treated only with growth medium
and assay reagent.
Statistical Analysis. The measured values were collected and
expressed as mean values ( standard deviation (s.d.). Statistical differ-
ences between raw data were investigated using the SigmaPlot 11.0 soft-
ware package with one-way ANOVA, in conjunction with a multiple
comparison test (Holm-Sidak).
’RESULTS
Gene Transfer Efficiency. In our preliminary experiments
usingHeLa cells, conventional chitosanswith different chain lengths
and degrees of acetylation exhibited extremely poor transfection
efficiencies or no transfection at all (data not shown). In contrast,
the self-branched and glycosylated chitosan previously devel-
oped in our laboratory16 showed a transfection efficiency com-
parable to that of commercial transfection reagents, such as
Exgen or Lipofectamine. Therefore, using HeLa cells as a model
cell line, we decided to focus on self-branched chitosans and
investigate the structure-activity relationships related to gene
transfer. As illustrated in Figure 1, self-branched chitosans both
with and without trisaccharide substitutions mediated transgene
expression in HeLa cells. The transgene expression peaked at
24-48 h and then rapidly declined, even when the cells were split
and kept under growing conditions.
However, the corresponding linear chitosan used as a starting
material for the synthesis of self-branched chitosans did not
transfect the cells. The same results were obtained with other
linear chitosans having MWs from 6 to 150 kDa and degrees of
acetylation from FA 0 to 0.2 (data not shown).
Next, we synthesized a series of completely de-N-acetylated
self-branched chitosans (FA < 0.002) with and without the
trisaccharide substitution. The synthesis and characterization
of these compounds has been recently reported elsewhere.19
As shown in Table 1, the branched chitosans had two- to three-
fold higher MWs (Mw) compared with their linear precursors,
reaching approximate Mw in the range of 10-70 kDa. Several
Figure 1. Time course of luciferase gene expression in HeLa cells trans-
fected using nanoparticles formed with linear (LIN), self-branched (SB),
and self-branched trisaccharide-substituted (SBTCO) chitosans at ami-
no-phosphate (N/P) ratios of 3-10. Data represent mean values( s.d.,
n = 4.
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nanoparticles varying in the relative amount of chitosan, deﬁned
as ratio between protonable amines and phosphate (N/P), were
prepared from each chitosan. The N/P ratios were chosen to
cover the interval of optimal performance for each chitosan and
varied due to large variation in the chitosan structures. For
comparison purposes, nanoparticles with a N/P ratio of 5 were
prepared from all chitosans. In total, 36 formulations were
prepared and used to transfect HeLa cells. Figure 2 shows the
dependence of gene transfer on the MW and amount of chitosan
in the formulation for SB and SBTCO chitosans.
In the case of the SB chitosans (Figure 2a), the highest luci-
ferase gene expression was mediated by formulations based on
SB10, SB20 and SB30. The substitution of self-branched chit-
osans by the AAM trimer resulted in a signiﬁcant increase in
transfection eﬃciency and the highest luciferase expression was
obtained with SBTCO20 and SBTCO30 (Figure 2b). Figure 2
also shows that luciferase gene expression decreased as theMw of
the chitosans increased above 40 kDa. For all chitosans, the trans-
fection eﬃciency varied with the N/P ratio of the polyplexes. The
optimal N/P ratio, where the maximum level of gene expression
was observed, decreased with increasing MW. The formulations
formed with SBTCO chitosan generally required higher N/P
ratios than those with SB chitosans of comparable MW.
On the basis of the results presented in Figure 2, the self-
branched chitosans SB30 and SBTCO30 were chosen for further
experiments, in which the transfection eﬃciency was directly
compared to their linear counterparts and two commercial trans-
fection reagents, Exgen (EXG) and Lipofectamine 2000 (LFN).
Figure 3a shows that LIN10, which was the starting material for
production of SB30, TCO10, and SBTCO30 was not able to
transfect the HeLa cells at all.
Substitution of LIN10 by AAM improved the ability to
transfect the HeLa cells, and TCO10 required a N/P ratio of
10 to mediate transgene expression. Self-branching of LIN10
had a similar positive eﬀect on transfection, and SB30 showed
optimal transfection at N/P ratios of 3 and 5. The combination of
self-branching and substitution was the most successful strategy
and SBTCO30 at N/P 10 mediated an approximately three-fold
higher luciferase expression level than SB30 and TCO10.
SBTCO30 was the most eﬀective gene carrier overall, showing
approximately two- and ﬁve-fold higher luciferase expression
levels than LFN and EXG, respectively (Figure 3a).
To compare the transfection eﬃciency of the chitosans at the
single-cell level, HeLa cells were transfected with the same
plasmid construct expressing GFP as a reporter and analyzed
by ﬂow cytometry. The results presented in Figure 3b show the
percentage of GFP-positive cells after transfection using pDNA-
chitosan nanoparticles based on LIN10, SB30, TCO10, SBTCO30,
LFN, and EXG. In a similar manner to Figure 3a, LIN10-media-
ted poor transfection, giving a percentage of positive cells similar
to that of naked pDNA. Transfection using SB30 resulted in up to
40% GFP-positive cells at N/P ratios of 3 and 5, whereas the
TCO10 transfected up to 20% of the cells. SBTCO30 mediated
the most successful transfection, reaching almost 70% transfection
of cells at a N/P ratio of 10, which is similar to the results for LFN.
Nanoparticle Uptake. Themost obvious reason for different
transfection efficiencies may be differences in the cellular uptake
of nanoparticles. Therefore, internalization of nanoparticles
containing YOYO-1-labeled pDNA by HeLa cells was investi-
gated. To distinguish between internalized and cell surface
bound nanoparticles resistant to extensive washing, we analyzed
the cells before and after incubation with TB, which is used as a
Figure 2. Eﬀect of MW on transfection eﬃciency of self-branched
chitosans. Luciferase gene expression 24 h after transfection using (a)
self-branched (SB) or (b) self-branched trisaccharide-substituted
(SBTCO) nanoparticles at diﬀerent N/P ratios. Data represents mean
values ( s.d., n = 4.
Figure 3. Eﬀect of self-branching and glycosylation on transfection
eﬃciency of chitosan in HeLa cells. Self-branched (SB), trisaccharide-
substituted (TCO), or self-branched trisaccharide-substituted
(SBTCO) chitosan were derived from linear chitosan (LIN) with a
Mw of 10 kDa. The commercially available transfection reagents Exgen
(EXG) and Lipofectamine 2000 (LFN) were also included. (a) Lucifer-
ase gene expression 24 h after transfection using pDNA-chitosan
nanoparticles prepared at N/P ratios of 3-10. SBTCO30 at a N/P ratio
of 10 yielded signiﬁcantly higher (p < 0.05) luciferase gene expression
compared with all other formulations. (b) Percentage of GFP-positive
cells 24 h after transfection. SBTCO30 at a N/P ratio of 10 yielded
signiﬁcantly higher (p < 0.05) percentage of GFP-positive cells compared
with all other formulations. Data represent mean values ( s.d., n = 4.
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quencher of extracellular fluorescence. Figure 4a shows that with
a few exceptions, typically >95% of cells in the population
internalized the nanoparticles.
The poor uptake of TCO10 at a N/P ratio of 3 likely resulted
from premature dissociation due to the poor physical stability of
TCO polyplexes at low N/P ratios. The percentage of YOYO-1-
positive cells remained very similar both in the presence and
absence of TB. However, Figure 4b shows that the relative
amount of internalized pDNA was strongly dependent on the
type of chitosan and the N/P ratio of the formulation. Further-
more, formulations based on LIN and SB chitosan showed a high
amount of extracellularly bound pDNA, as evidenced by the
substantial reduction in FI after incubation of the cells with TB.
Themedian values of FI following the TB treatment presented
in Figure 4b show that TCO10 and SBTCO30 chitosans
mediated the highest uptake of pDNA. The cells transfected
with these chitosans showed relatively low amounts of surface-
bound nanoparticles. Compared with SBTCO30, a lower amount
of pDNA was delivered by SBTCO70. The ﬂuorescence dis-
played by the cells transfected with the LIN and SB chitosans was
signiﬁcantly quenched by TB and was therefore mediated by
extracellular nanoparticles. In the formulations with increasing
amounts of chitosan, such as LIN10 and SB30 at a N/P ratio of
10, the median FI decreased 22- and 12-fold, respectively, after
incubation with TB. Therefore, Figure 4b demonstrates that the
HeLa cells transfected with TCO and SBTCO chitosans inter-
nalized most pDNA, whereas cells transfected with LIN and SB
chitosans exhibited a high amount of cell surface-associated pDNA.
Compared with chitosans in general, transfections performed with
EXG or LFN led to a weak internalization of pDNA. Figure 4b
conﬁrms that naked pDNA was not taken up by the cells.
The cellular uptake of polyplex formulations of LIN10, SB30,
and SBTCO30 at a N/P ratio of 5 was also investigated by
CLSM, as presented in Figure 4c. These images show large
aggregates of LIN10 and SB30 nanoparticles bound to the cell
surface, and only a few particles appear to have been internalized.
In contrast, cells transfected with SBTCO30 showed fewer
extracellular nanoparticles, and the internalized nanoparticles
were smaller andmore abundant compared with cells transfected
with LIN10 or SB30.
Figure 4. Cellular uptake of pDNA-chitosan polyplexes in HeLa cells. To distinguish between cell-surface-bound and internalized nanoparticles, the
cells were quenched with trypan blue (TB). Gray bars show measurements after TB treatment (corresponding to internalized pDNA), whereas white
bars show the measurements in the absence of TB (corresponding to both surface-bound and internalized DNA). (a) Percentage of YOYO-1-positive
cells after the uptake of pDNA-chitosan polyplexes. (b) Relative amount of internalized pDNA expressed as median ﬂuorescence intensity (FI) of the
YOYO-1-positive cells. Data represent mean values( s.d., n = 4. (c) Representative CLSM images of HeLa cells incubated for 2 h with polyplexes of (A)
LIN10, (B) SB30, or (C) SBTCO30 at a N/P ratio of 5. The chitosans were labeled with Alexa Fluor 488 (green), pDNA was labeled with YOYO-1
(red), and the cellular plasma membrane was stained with CellMask (blue). The bar size is 20 μm.
726 dx.doi.org/10.1021/bm1013525 |Biomacromolecules 2011, 12, 721–729
Biomacromolecules ARTICLE
Formulation Stability. Because of differences in the apparent
size of the nanoparticles, as revealed in the CLSM images
(Figure 4c), we investigated the colloidal stability of different
chitosan formulations after dilution in a CO2-saturated hyper-
tonic Opti-MEM at 37 C. Previously, it has been shown that
AAM-substitution of chitosan renders the nanoparticles more
stable toward aggregation.16 However, the analysis was per-
formed in PBS or in Hanks balanced salt solution and not in a
cell culture medium under conditions identical to the transfec-
tion experiment. Initially, all pDNA-chitosan nanoparticles
prepared in MQ water had comparable z-average hydrodynamic
diameters of approximately 80-100 nm (Table 2, Supporting
Information). However, following dilution in cell culture media
at 37 C, the nanoparticles rapidly increased in size and aggre-
gated (Figure 5).
The rate of aggregation was strongly dependent on the type of
chitosan and the N/P ratio of the formulation. Figure 5a shows
that in the case of nanoparticles formed with the unsubstituted
chitosans, SB30 nanoparticles aggregated to a lower extent than
LIN10. For both chitosans, the aggregation rate increased as the
N/P ratio was increased from 3 to 10. The AAM substitution of
chitosan clearly reduced the rate of aggregation (Figure 5b).
However, formulations of SBTCO30 still formed aggregates with
a z-average diameter of ∼600 nm over 30 min. Surprisingly, no
eﬀect of the N/P ratio on the aggregation rate was observed for
SBTCO30. In contrast, the formulation prepared from SBTCO70
at a N/P ratio of 30 showed no aggregation at all, and the nano-
particles remained well below 200 nm in diameter.
Nanoparticle Cytotoxicity. Changes in chain architecture of
chitosan may have an influence on the cytotoxicity of this com-
pound. Therefore, cytotoxicity mediated by pDNA-chitosan
formulations was investigated using the Alamar blue assay, and
themetabolic activity of HeLa cells wasmeasured 4 and 24 h after
transfection. Figure 6a shows that cells treated with SBTCO
chitosans of different MW retained high metabolic activity after
transfection. No obvious relationship between MW and cyto-
toxicity was found.
However, a few formulations of SBTCO40 and SBTCO60
mediated a minor but signiﬁcant decrease in metabolic activity
compared with untreated cells. Furthermore, Figure 6b shows
that the self-branching of chitosan did not result in higher toxicity
compared with their linear counterparts. When comparing the
cytotoxicity of chitosans with that of the commercial transfection
reagents (Figure 6b,c), it is apparent that both EXG and LFN
exerted signiﬁcantly higher toxicity. The metabolic activity in
cells treated with EXG and LFN was further reduced 24 h after
transfection, whereas cells transfected using chitosan remained
unaﬀected. As shown in Figure 6c, cells treated with EXG or LFN
also displayed severe changes in morphology 24 h after transfec-
tion, whereas the chitosan-treated cells appeared comparable to
untreated cells.
’DISCUSSION
This study demonstrates that self-branching of chitosan yields
eﬃcient and safe gene delivery in cells not transfected by linear
chitosans. The interest in branched chitosan architectures was
initiated by a recent study in which self-branching was used as a
tool to increase the physical stability of polyplexes formed with
glycosylated chitosan oligomers.16 The resulting self-branched
and glycosylated chitosan has been shown to possess higher
solubility at pH > 7 and mediated signiﬁcantly higher transgene
expression than the optimized linear oligomers in HEK293 and
HepG2 cells.16 Therefore, we decided to investigate system-
atically transfection eﬃciency of branched chitosans and identify
structures with high gene transfer eﬃciency.
As shown in this study, the transfection eﬃciency of self-
branched chitosans was found to depend onMW, and the highest
gene transfer was obtained using formulations with a certain
combination of MW and N/P. Because MW and N/P determine
physical stability of nanoparticles,8,10,22 the structure-activity
relationship observed in Figure 2 may be explained in terms of a
balance between polyplex stability and unpacking. The eﬃcient
gene transfer mediated by nanoparticles formed with SB/
SBTCO20-30 indicates that these possess optimal stability,
allowing the intracellular unpacking and expression of pDNA.
Increasing the MW of the chitosan lead to more stable poly-
plexes10 that may dissociate too slowly, as recently shown by
Thibault et al.11 To maintain transgene expression, the resulting
higher MW must be compensated by a lower N/P ratio and vice
versa (Figure 2). Nanoparticles falling outside the optimal
stability window are likely to possess interaction strengths that
are too high or too low between the chitosan and pDNA. One
example of the former is the nanoparticles formed with highMW
chitosans, such as SB/SBTCO60-70, especially at a high N/P
ratio. For the AAM-substituted SBTCO chitosans, the range of
optimal stability was shifted toward higher N/P ratios and higher
MW (Figure 2b). This was likely a consequence of the glycosyla-
tion, which has been previously shown to weaken the physical
stability of pDNA-chitosan nanoparticles.10,16
It has been previously reported that HeLa cells are diﬃcult to
transfect with chitosans.12,13 The discovery that only self-branched
but not linear chitosans eﬃciently transfected HeLa cells was
rather surprising. Direct comparison of chitosans derived from
the linear chitosan LIN10 (Figure 3), which was previously
Figure 5. Time-dependent aggregation of pDNA-chitosan polyplexes
during transfection. (a) Aggregation of polyplexes formed with unsub-
stituted chitosans LIN10 and SB30 at N/P ratios of 3-10. (b)
Aggregation of polyplexes formed with substituted chitosans SBTCO30
and SBTCO70 at N/P ratios of 5-30. The z-average hydrodynamic
diameter of the particles was measured after diluting the samples with an
equal volume of CO2-saturated hypertonic Opti-MEM to obtain
isotonic formulations with a pH of 7.2 and an osmolarity of 300
mOsm/kg. Data represent mean values ( s.d., n = 3.
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tailored for the transfection of HEK293 cells, demonstrates that
the molecular architecture of chitosan is crucial for gene transfer
performance. The combination of self-branching and substitu-
tion of the linear chitosan resulted in a high transfection
eﬃciency, exceeding that of EXG and LFN (Figure 3). The lack
of transgene expression using the linear chitosans may be related
to poor uptake or poor intracellular traﬃcking. As previously
reported, the polyplexes of LIN, TCO, and SBTCO possessed
similar sizes and properties.16,23 However, the nanoparticles of
TCO and SBTCO have been shown to be less prone to aggrega-
tion at physiological pH values.16 Despite aggregation, the linear
chitosans showed high uptake levels and were able to transfect
HEK293 cells.8,10 This illustrates cell-line-speciﬁc diﬀerences
related to the uptake and cellular processing of the diﬀerent
nanoparticles, as previously reported by von Gersdorﬀ.24 HeLa
cells may be unable to take up larger aggregates, or, alternatively,
diﬀerent endocytic mechanisms may be involved in the uptake
and intracellular traﬃcking of diﬀerent types of nanoparticles.
These diﬀerences may also be due to a diﬀerent occurrence of
chitosan-degrading enzymes in the endosomes, making protec-
tion of the pDNA more important in certain cell lines.
For most chitosan formulations, the eﬃciency of transfection
on the single-cell level correlates with the amount of transgene
produced, indicating a similar level of GFP-production per cell.
EXG gives a relatively high percentage of positive cells but still
yields very low levels of luciferase transgene expression. This may
also indicate high cytotoxicity because dying cells will be exclu-
ded from ﬂow cytometry analysis but not from the luciferase
analysis.
The diﬀerences in transfection eﬃciency of the chitosans
cannot only be explained by relative diﬀerences in cellular uptake
levels of the nanoparticles. All chitosan nanoparticles showed
eﬃcient cellular uptake compared with naked pDNA, but there
was no correlation between the percentage of YOYO-1-positive
cells in Figure 4a and the transfection eﬃciency.
Although almost all cells internalized the nanoparticles, there
were large diﬀerences in the relative amount of cell surface
bound and internalized pDNA among the diﬀerent formulations
(Figure 4b). The amount of DNA delivered by LIN formulations
was considerably lower compared with the other chitosans and
may thus be a reason for the poor transfection eﬃciency. Further-
more, most chitosan formulations showing poor cellular uptake
also mediated poor transfection (Figure 3a). In general, formula-
tions with higher N/P ratio seem to have reduced amounts of
internalized pDNA but higher levels of transgene expression.
However, cells transfected with LFN and EXG also exhibited
Figure 6. Metabolic activity of transfected HeLa cells relative to untreated cells measured by the Alamar blue assay. Activity was measured 4 h (gray
bars) and 24 h (white bars) after transfection using pDNA formulated with (a) self-branched chitosans of diﬀerent MW and (b) chitosans varying in
molecular architecture (LIN10, SB30, TCO10, SBTCO30), Exgen (EXG), and Lipofectamine (LFN). Data represent mean values ( s.d., n = 4.
Formulations that yielded signiﬁcantly reduced (p < 0.05) metabolic activity compared with untreated cells are indicated with asterisks (“*”). (c)
Representative microscopy images at 10magniﬁcation of (A) untreated HeLa cells and (B) cells 24 h after treatment with SB30 at N/P 5 or complexes
of (C) EXG at N/P 5 or (D) LFN at a weight ratio of 3.
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very low uptake of pDNA, with levels comparable to the LIN
formulations, but they showed reasonably high levels of luciferase
expression. Therefore, the relationship between the amount of
internalized pDNA and the amount of transgene produced seems
to be strongly carrier-dependent. This indicates that LFN and
EXG transfection leads to more eﬃcient intracellular processing
of internalized pDNA, which has also been suggested in several
previous studies.25-27
The extensive binding of LIN and SB nanoparticles to the cell
surface seemed to increase with N/P ratio and was accompanied
by decreasing amount of internalized pDNA. This may be a
consequence of increasing amounts of free chitosan in the
formulations, which competes for cell-surface binding. It has
been previously shown that at a N/P ratio of 10, 50-70% of the
chitosan in polyplex formulations is unbound to pDNA.23 The
higher uptake of SB nanoparticles compared with LIN, despite a
similar extent of cell surface binding, may be related to a lower
aggregation rate of SB nanoparticles.
The CLSM images (Figure 4c) qualitatively conﬁrm the ﬂow
cytometry data, showing large amounts of extracellular LIN and
SB nanoparticles that appear to be aggregated. On the contrary,
cells transfected with SBTCO exhibited mostly intracellular
nanoparticles. The DLS analysis of the formulations performed
under transfection conditions conﬁrmed the aggregation (Figure 5).
Apparently, the aggregating formulations made from linear
chitosans sediment on and bind to cell surfaces. The internaliza-
tion of large aggregates is clearly limited and leads to accumula-
tion of aggregated nanoparticles and free chitosan. SB chitosans
also showed aggregation and extensive binding to the cell surface
(Figure 4c), and CLSM did not show any apparent diﬀerences
compared to LIN. However, because SB nanoparticles were
taken up (Figure 4b) and able to transfect the cells (Figures 2
and 3), CLSM failed to visualize these intracellular complexes in
the presence of the large and highly ﬂuorescent aggregates.
Interestingly, there was no straightforward correlation be-
tween the extent of polyplex aggregation (Figure 5) and gene
transfer eﬃciency (Figures 2 and 3). The most stable formula-
tion, SBTCO70 at a N/P ratio of 30, mediated poor gene transfer
(Figure 2b). The aggregating formulations of SBTCO30 were far
more eﬃcient. Similarly, the two SBTCO30 formulations
showed a similar degree of aggregation but exhibited diﬀerent
transfection eﬃciencies. This indicates that colloidal stability of
formulation itself does not guarantee successful gene transfer.
However, a high degree of aggregation seems to correlate with
poor transfection. For instance, the formulations with the highest
degree of aggregation, LIN10 with a N/P ration of 3 or 10 and
SB30 with an N/P ratio of 10, failed to transfect the HeLa cells.
However, the polyplexes of SB30 (N/P ratio of 3), TCO10, and
SBTCO30 (N/P ratio of 30) that had lower degrees of aggrega-
tion were able to mediate the most eﬃcient transfections.
Therefore, strategies to increase the colloidal stability of chitosan
nanoparticles without negatively inﬂuencing the physical stability
and cellular uptake are needed. Such strategies could include the
grafting of chitosan with polyethylene glycol (PEG), which has
been previously shown to prevent aggregation in the presence of
serum and bile.28 Another possible approach is to coat the
nanoparticles with multivalent polymers, such as copolymers of
N-(2-hydroxy-propyl)methacrylamide (PHPMA), as described
by Oupicky et al.29
The chitosan-based nanoparticles presented in this study were
based solely on chitosan and no other synthetic components,
thereby maintaining the high safety proﬁle that is a hallmark of
chitosan. The analysis of post-transfection cellular metabolic
activity and the morphological observation of the transfected
cells (Figure 6) once again conﬁrm the low toxicity of chitosan.
Although some formulations showed a subtle but signiﬁcant
reduction in metabolic activity, these eﬀects were minor com-
pared with EXG or LFN, which also exerted a visible eﬀect
on cellular morphology (Figure 6c). This result correlates well
with many previous studies, implying that chitosan is a safe
nonviral vector for potential use as a vector in gene therapy in
vivo.22,28,30-32
’CONCLUSIONS
This study shows that small modiﬁcations in the chitosan
architecture, such as the self-branching of linear chitosan, that do
not involve substantial changes in chemical composition can
profoundly enhance gene transfer performance. The poor trans-
fection eﬃciency of linear chitosans in HeLa cells seems to be
related to low cellular uptake because of poor formulation
stability and extensive binding of the aggregated nanoparticles
to the cell surface. Compared with linear chitosans, nanoparticles
formed with self-branched chitosans show higher colloidal
stabilities and enhanced cellular uptake levels and were able to
mediate high transgene expression in HeLa cells. The glycosyla-
tion of self-branched chitosans reduced extensive binding to the
cell surface and improved the uptake of nanoparticles. However,
high uptake of nanoparticles did not always correlate with high
transgene expression. Only the nanoparticles within a certain
range of MW and N/P ratio yielded eﬃcient gene transfer,
indicating the importance of the balance between DNA protec-
tion and DNA dissociation. Structure-activity relationships
revealed that self-branched chitosans in the Mw range of 20-
30 kDa are the most potent gene transfer vehicles, showing high
transfection eﬃciencies and low cytotoxicity.
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Chitosan has gained increasing interest for siRNA delivery. Although chitosan covers a family of structurally
different polysaccharides, most siRNA delivery studies have been performed with conventional partially N-
acetylated chitosans. Herein, the purpose was to identify fundamental chitosan molecular properties favoring
siRNA delivery and efﬁcient gene silencing in mammalian cells. Nanoparticles were prepared from well-
deﬁned chitosans of various chemical compositions, degrees of polymerization (DPn) and chain architectures.
Structure-activity relationships were determined by the cellular uptake of siRNA and the knockdown efﬁ-
ciency at mRNA and protein levels. Additionally, the nanoparticle cytotoxicity was evaluated on the basis
of cellular metabolic activity and membrane integrity. Our results show that the most efﬁcient gene silencing
was achieved using fully de-N-acetylated chitosans with intermediate chain lengths (DPn 100–300). These
chitosans mediated efﬁcient siRNA delivery at low siRNA concentrations and, in several cell lines, potent
long-term silencing of both exogenous and endogenous target genes, with minimal cytotoxicity.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
RNA-interference (RNAi) represents a new and potent strategy for
post-transcriptional gene silencing that can be mediated by delivery
of synthetic double-stranded small interfering RNA (siRNA). This pro-
cess results in the degradation of homologous mRNA and thereby
causes knockdown of the speciﬁc target-gene. RNAi is well established
as a tool for studying gene function [1] and has shown promising ther-
apeutic possibilities for the treatment of cancer [2], viral infections [3],
and inﬂammatory diseases [4]. Despite its many promises, the intracel-
lular delivery of siRNA has proved difﬁcult because these macromole-
cules (~13 kDa) are easily degraded by nucleases and cannot cross cell
membranes. Consequently, siRNA cannot be efﬁciently transported
into cells without the aid and protection of suitable carriers.
One of the candidates for nucleic acid delivery that has gained
considerable attention during the last decade is chitosan. Chitosan is
a family of biopolymers derived from chitin, composed of β-1,4 linked
N-acetylated D-glucosamine (GlcNAc; A-unit) and D-glucosamine
(GlcN; D-unit). Chitosans can be prepared with widely varying con-
tent of GlcNAc and chain lengths [5]. One of the main advantages of
chitosans in biomedical applications is their excellent biocompatibil-
ity and safety proﬁle, in addition to being biodegradable in humans
[6,7]. Chitosan has repeatedly been shown to possess low toxicity
both in vitro [8–10] and in vivo [11] without causing any deleterious
immunologic responses [11].
Chitosan is a weak polybase with a pKa that is close to 6.6 [12], and
its charge density, thus, strongly depends on the pH. The high degree of
protonization of amino groups at pH values below the pKa strongly fa-
vors electrostatic interactions with polyanionic molecules such as
DNA or siRNA, leading to the formation of nanosized particles with dif-
ferent shapes and properties [13,14]. A low-charge density at physio-
logical conditions contributes to low cytotoxicity and may facilitate
intracellular release of siRNA from the nanoparticles, but may also
lead to premature dissociation of the nanoparticles. To circumvent pre-
mature dissociation, the nanoparticles are often stabilized by ionic
crosslinkers such as tripolyphosphate, or, alternatively, chitosan is quar-
ternized by the trimethylation of amino groups [15–17]. However,
these approaches may lead to excessive stability of the nanoparticles
and increased cytotoxicity.
The chitosan family offers enormous structural and functional ver-
satility. It has been clearly demonstrated in studies on plasmid DNA
delivery that tailoring of the degree of polymerization (DPn), the frac-
tion of N-acetylated units (FA) and the chain architecture is essential
to optimizing the delivery efﬁciency of the nanoparticles [8,9,18-
20]. Compared to DNA delivery, relatively little is known about the ef-
fect of the chitosan carrier on siRNA delivery efﬁciency. Most studies
employing chitosan for siRNA delivery have been performed using
conventional partially de-N-acetylated chitosans with FA>0.15 and
high N/P ratios. There are a few reports showing that chitosans with
higher charge densities and higher molecular weights mediate more
efﬁcient siRNA delivery than those with high FA and low DPn
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[13,16,17,21]. However, no systematic investigation that includes a
broader range of less conventional chitosans has yet been performed.
The overall goal of this study was to identify the molecular prop-
erties of chitosans that favor the cellular uptake of siRNA and an efﬁ-
cient knockdown of genes. By using well-deﬁned and characterized
chitosans prepared in our laboratory to formulate the nanoparticles,
the efﬁciency of siRNA delivery was determined both on endogenous-
ly expressed and stably transfected target genes. In addition, off-
target effects as well as nanoparticle-mediated toxicity were evaluat-
ed. We show that fully de-N-acetylated linear chitosans of DPn>50
efﬁciently mediate gene silencing at low doses and in different cell
lines, including primary cells, with minimal toxic effects.
2. Materials and methods
2.1. siRNA
The following siRNAs used in this study were predesigned and
supplied by Ambion: anti-EGFP (Silencer), anti-GAPDH (Silencer) in
addition to a non-targeting (NT) siRNA sequence (Silencer, Negative
Control #1). For ﬂow cytometry, a NT Alexa-647 conjugated siRNA
duplex (AllStars Negative Control, Qiagen) was used.
2.2. Transfection reagents
The chitosans used in this study are described and characterized in
Table 1.
All of the fully de-N-acetylated chitosans used in this study were
prepared in our laboratory from shrimp chitin. Chitosans with de-
grees of polymerization (DPn) ranging from approximately 50 to
300 monomers were prepared by nitrous acid depolymerization and
NaBH4 reduction of a fully de-N-acetylated chitosan (FAb0.002), as
previously described [22]. The self-branched chitosan was prepared
by omitting the reduction step and incubating the chitosan solution
under selective reduction conditions (NaCNBH3) for 48 h [23]. Glyco-
sylation of the self-branched chitosan using the trimer 2-acetamido-
2-deoxy-D-glucopyranosyl-β-(1–4)-2-acetamido-2-deoxy-D-gluco-
pyranosyl-β-(1–4)-2,5-anhydro-D-mannofuranose (AAM) was per-
formed as previously described [24]. The partially N-acetylated
chitosan (FA 0.15) was provided by Pronova Biopolymers (Drammen,
Norway).
To determine the FA and the degree of substitution (d.s.), the chit-
osan samples were characterized by 1H NMR (Avance DPX 400, Bru-
ker). The weight and number averages of the molecular weight and
the polydispersity distributions were determined by size-exclusion
chromatography (SEC) with a refractive index detector (RI, Dawn
Optilab 903, Wyatt Technology) and a multiangle laser light scatter-
ing detector (MALLS, Dawn DSP, Wyatt Technology). All samples
were dissolved in Milli-Q (MQ) deionized water (5–7 mg/mL) and ﬁl-
tered through a 0.22 μm syringe ﬁlter (Millipore). A TSK 3000 PWXL
column (Tosoh Bioscience) was used, and the sample was eluted
with 0.2 M ammonium acetate (pH 4.5) at a low ﬂow rate of
0.5 mL/min.
The four different structure types of chitosanoligomers are denoted as
linear (LIN), self-branched (SB), self-branched trisaccharide-substituted
(SBTCO), and N-acetylated (FA). The number used in the notation is the
measured DPn, while the N-acetylated chitosan is denoted by its fraction
of N-acetylated units.
The lipid-based transfection reagent Lipofectamine RNAiMAX
(RiM) was purchased from Invitrogen, and lipoplexes were prepared,
as described in the manufacturer's protocol at 13.3 μl RiM/μg siRNA.
2.3. Preparation of siRNA-chitosan nanoparticles
Formulations with different amino/phosphate (N/P) ratios were
prepared by a self-assembly method while keeping the amount of
siRNA constant (1.2 μg/mL). A solution of siRNA (5 μM, 6.65 μg/mL)
was diluted with the necessary amount of sterile nuclease free
water (5 Prime). Subsequently, the required amount of chitosan
was added from a sterile ﬁltered solution (0.1 mg/mL) during vortex
mixing (1200 rpm). The assembled nanoparticles were incubated for
30 min at room temperature before transfection. When assembling
the nanoparticles for transfection at different doses, the particles
were ﬁrst made at the highest concentration and incubated for
30 min before serial dilution.
2.4. Size determination of nanoparticles
The sizes of the nanoparticles were determined using dynamic light
scattering (DLS) on a Zetasizer Nano ZS (Malvern Instruments). Mea-
surements were performed in MQ water at a 173° angle and a temper-
ature of 25 °C. The size is expressed as the z-average hydrodynamic
diameter obtained by a cumulative analysis of the correlation function
using the viscosity and refractive index of water in the calculations.
2.5. Cell culture
The transduced H1299 cell line (human lung carcinoma) stably
expressing destabilized EGFP (Enhanced Green Fluorescent Protein)
was a gift from Prof. Jørgen Kjems (Dept. of Molecular Biology, Aarhus
University, Denmark). The cells were grown in RPMI 1640 medium
(Sigma) supplemented with 1 mM non-essential amino acids (Gibco,
Invitrogen), 10% FBS (Gibco, Invitrogen) and 500 μg/mL G418 selection
antibiotic (Sigma). MCF-7 (human breast cancer) cells were provided
by Kristin G. Sæterbø (Dept. Physics, NTNU) andHUVEC (humanumbil-
ical vein endothelial) cells were supplied by Lonza. MCF-7 cells were
grown in MEM (Gibco, Invitrogen) with 1 mM non-essential amino
acids, 1 mM sodium pyruvate (Gibco, Invitrogen) and 10% FBS. The
HUVEC cells were grown in EBM-2 (Lonza) with full supplements
(EGM-2 BulletKit, Lonza). When seeding cells for experiments, growth
media supplemented with 100 U/mL of penicillin and streptomycin
(PEST, Sigma) was used. The cells were cultivated at 37 °C in a humidi-
ﬁed atmosphere with 5% CO2.
2.6. In vitro transfection
Cells were seeded in tissue culture wells 24 h prior to experiments
in densities with approximately 50–75% conﬂuency on the day of
transfection. For example, 7500 cells in 100 μl growth medium were
seeded in 96-well plates (Corning CellBIND). The nanoparticles as-
sembled in water were diluted with an equal volume of Opti-MEM
Table 1
Characterization of the chitosans included in the study. The chitosans are denoted
according to their chemical composition or molecular architecture: linear (LIN), N-
acetylated (FA), self-branched (SB), and self-branched trisaccharide substituted
(SBTCO). The weight and number averages of the molecular weight (Mw, Mn) and
the polydispersity index (PDI) were analyzed by SEC-MALLS. The degree of AAM-
substitution (d.s.) and the fraction of N-acetylated units (FA) were determined by 1H
NMR.
Notation DPn Mn Mw PDI Chain architecture FA d.s.
kDa kDa % AAM
LIN50 54 10.8 16.4 1.52 Linear b0.002 0
LIN100 105 20.9 34.8 1.67 Linear b0.002 0
LIN150 156 31.3 54.6 1.74 Linear b0.002 0
LIN200 199 39.8 74.5 1.87 Linear b0.002 0
LIN250 247 49.5 100.3 2.03 Linear b0.002 0
LIN300 320 64.1 141.6 2.21 Linear b0.002 0
FA0.15 320 63.8 188.7 2.96 Linear 0.15 0
SB150 167 33.4 67.4 2.02 Self-branched b0.002 0
Self-branched
SBTCO150 170 33.9 71 2.09 AAM b0.002 8.3
substituted
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(Gibco, Invitrogen), supplemented with 270 mM mannitol (Sigma)
and 20 mM HEPES (Sigma) for adjustment of the osmolarity to
300 mOsm/kg and pH to 7.2. The formulations were not supplemen-
ted with FBS or antibiotics. Prior to adding the nanoparticles, the
cells were washed and brieﬂy incubated with 100 μL/well of Hanks
balanced salt solution (HBSS, Gibco, Invitrogen) at 37 °C and 5% CO2.
Next, HBSS solution was removed and 50 μl aliquots of nanoparticle
formulation containing typically 0.03 μg (45 nM) siRNA were added
to each well in 96-well plates. The formulations were removed after
5 h of incubation and replaced by 200 μl of growth media supplemen-
ted with PEST.
2.7. Flow cytometry
EGFP knockdown and cellular uptake of siRNA were measured
using a Gallios ﬂow cytometer (Beckman Coulter) and data were an-
alyzed and visualized using the Kaluza software package (Kaluza Flow
Cytometry Analysis v1.1, Beckman Coulter). Knockdown was mea-
sured 48 h after transfection with anti-EGFP siRNA. The cells were
washed in PBS (Gibco/Invitrogen), trypsinized, resuspended in ice-
cold PBS supplemented with 5% FBS, ﬁltered through 40 μm nylon
mesh (BD) and kept on ice until the time of analysis. The cellular up-
take of siRNA was determined by transfection with Alexa-647 conju-
gated siRNA (Qiagen). After incubating with polyplexes for 4 h, the
cells were washed with PBS and further incubated with RPMI for
30 min. Afterwards, the cells were incubated with heparin supple-
mented RPMI (1 mg/mL, Sigma) for 30 min before they were har-
vested and analyzed.
For each sample, 10,000 gated events were counted and a dot plot
of forward scatter versus side scatter established a collection gate for
cells to exclude cellular debris, dead and aggregated cells. The EGFP or
Alexa-647 positive cells were excited using a 488 nm or 633 nm laser
line, respectively. Emitted light was collected at FL1 or FL6 using a
525/40 nm or 660/20 nm band pass ﬁlter, respectively. Untreated
cells were analyzed to determine the normal level of EGFP ﬂuores-
cence intensity. The knockdown of EGFP in transfected cells was cal-
culated from the number of EGFP positive cells or median
ﬂuorescence intensity (FI) relative to the untreated cells. To deﬁne
the Alexa-647 positive cells, untreated cells were analyzed as nega-
tive controls, to set a threshold for the ﬂuorescence intensity above
the level of autoﬂuorescence. The relative amount of internalized
Alexa-647 was estimated from the median FI of the Alexa-647 posi-
tive population.
2.8. GAPDH knockdown
Knockdown of the ubiquitously expressed endogenous gene
GAPDH (glyceraldehyde-3-phospate dehydrogenase) was measured
at mRNA level using the ABI 7500 real-time PCR system (Applied bio-
systems). The mRNA was harvested, and cDNA was synthesized and
ampliﬁed using the Cells-to-CT kit (Applied Biosystems) as described
in the manufacturer's protocol. Reverse transcription was performed
at 37 °C for 60 min. Quantitative Real-Time PCR (qRT-PCR) was per-
formed using the following cycle conditions: 95 °C for 10 min, 40 cy-
cles at 95 °C for 15 s, and 60 °C for 1 min. The following primers
(Euroﬁns MWG Operon) were used: GAPDH forward 5′-TGGGCTA-
CACTGAGCACACG-3’, GAPDH reverse 5′-CAGCGTCAAAGGTGGAGAG-
3′, β-actin forward 5′-TCCACCTTCCAGCAGATGTG-3′, and β-actin re-
verse 5′-GCATTTGCGGTGGACGAT-3′. The primer efﬁciencies were
determined using standard curves. The percentage of mRNA expres-
sion relative to untreated cells or cells treated with NT siRNA was cal-
culated using the comparative Ct method, where the target sample
was normalized to endogenous β-actin.
The effect of the knockdown on the GAPDH protein activity was
measured using the KDalert GAPDH assay kit (Ambion) according to
the manufacturer's protocol, where the amounts of lysate and assay
reagents were halved, and measurements were performed in half-
area 96-well plates (Corning) at 615 nm using a spectrophotometer
(Molecular Devices).
2.9. CLSM
H1299 cells were seeded onto 8-chamber microscopic slides
(Ibidi) and transfected with anti-EGFP siRNA, as described previously.
After 48 h, the cells were treated with 5 μg/mL of CellMask plasma
membrane stain (Invitrogen). Live cells were examined using an
LSM 510 (Carl Zeiss) confocal laser scanning microscope (CLSM)
equipped with a c-Apochromat 40×/1.2 NA W corr objective. EGFP
and CellMask were excited using 488 nm argon and 633 nm HeNe
laser lines, respectively. The emitted light was collected using a 500/
30 nm band pass and 650 nm long pass ﬁlters. The acquired images
had resolutions of 512×512 pixels.
2.10. Toxicity
The effect of transfection on the metabolic activity was measured
using an Alamar blue assay (Invitrogen). Cells were seeded in wells
and transfected with anti-EGFP siRNA, as previously described. A vol-
ume of 10 μl of the Alamar blue assay reagent that was diluted in
100 μl of growth medium was added to the cells at 4- and 48-h post-
transfection. The sample absorbances were measured 4 h after adding
the assay reagent using a spectrophotometer at 570- and 600-nm. The
metabolic activity of the cells was evaluated as a percentage reduction
of the Alamar blue reagent relative to the untreated cells (that received
only growth medium and assay reagent).
Possible deleterious effects on the cellular membrane as a conse-
quence of transfection were evaluated using the LDH cytotoxicity
assay (Cayman), which measured levels of cellular cytoplasmic LDH
leakage. This assay was performed at conditions similar to the Alamar
blue assay. Measurements of absorbance were performed 48 h post-
transfection in serum-free medium as suggested in the manufac-
turer's protocol. The amounts of cell suspension and assay reagents
were halved, and measurements were performed in half-area 96-
well plates at 490-nm using a spectrophotometer.
2.11. Statistical analysis
The measured values were collected and expressed as mean
values±standard deviation (s.d.). Statistical differences between
raw data were investigated using the SigmaPlot 11.0 software pack-
age with one-way ANOVA, in conjunction with a multiple comparison
test (Holm-Sidak).
3. Results
3.1. siRNA uptake and silencing of EGFP in H1299 cells
Four structurally different chitosans, including completely de-N-
acetylated linear (LIN150), self-branched (SB150), self-branched
trisaccharide-substituted (SBTCO150), and a partially N-acetylated
linear chitosan (FA0.15) were compared for their ability to deliver
siRNA and to mediate knockdown. Structure-activity relationships
for nanoparticles prepared from these chitosans were evaluated by
measuring the uptake of siRNA and silencing the stably expressed
EGFP in H1299 cells using ﬂow cytometry.
As illustrated in Fig. 1A and B, which show the median cellular
ﬂuorescence intensities (FI) of Alexa-647 conjugated siRNA, the
siRNA was typically internalized by almost all of the cells (Fig. 1B)
but the amounts varied with the type of chitosan carrier (Fig. 1A).
The partially N-acetylated (FA0.15) and substituted (SBTCO150) chit-
osans mediated higher uptakes compared to the linear chitosan
(LIN150), the self-branched chitosan (SB150), and the commercial
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lipid based vector RNAiMAX (RiM). Although, most of the cells
appeared to internalize even the naked siRNA as shown in Fig. 1B,
the relative amounts of siRNA taken up by the cells were insigniﬁcant
(Fig. 1A).
Following the uptake conﬁrmation, we examined the degree of
EGFP knockdown in H1299 cells using anti-EGFP (targeting, T)
siRNA or non-targeting (NT) negative control siRNA. Fig. 1C and D
show that nanoparticles based on the fully de-N-acetylated LIN150
and SB150 mediated the most efﬁcient knockdown, giving ~5% of
both the median FI and number of EGFP positive cells compared to
the untreated cells. In contrast, when using the partially N-
acetylated chitosan FA0.15 or the substituted SBTCO150 as delivery
vehicles, 68% and 85% of the cells still expressed EGFP, respectively.
However, the FI was reduced to 41% and 61% of the FI in untreated
cells, respectively. Interestingly, cells transfected with NT siRNA
using SB150, LIN150 and RiM showed increased EGFP expression
compared to untreated cells; an increase in FI of approximately 50%
was typically recorded (Fig. 1C). Such an increase in the EGFP expres-
sion was not observed when NT siRNA was delivered by FA0.15 and
SBTCO150. The knockdown of EGFP in the H1299 cells was qualita-
tively conﬁrmed by CLSM, as shown in Fig. 1E.
Based on the results in Fig. 1, which show promising delivery of
siRNA with fully de-N-acetylated linear chitosan, this type of chitosan
was selected to elucidate the effect of the chain length (expressed as
DPn) on siRNA uptake and knockdown efﬁciency in H1299 cells.
Again, almost 100% of the gated cells internalized siRNA independent
of the formulation (naked siRNA 92%), even when delivered at a con-
centration of 45 nM (data not shown). However, the median FI of
Alexa-647 conjugated siRNA was dependent on both the N/P ratio
and the chain length. As illustrated in Fig. 2A, the uptake of siRNA in-
creased when the N/P ratios were increased from 10 to 60. The siRNA
uptake also increased with the chain length of the chitosans, howev-
er, only for chitosans with a DPn below 200. As shown in Fig. 2B, all
chitosans with chain lengths in the range of DPn 150–300 mediated
efﬁcient knockdown at N/P ratios of 10, 30 and 60. Only the chitosan
with DPn 50 (LIN50) required an N/P ratio of 60 to obtain comparable
knockdown efﬁciency. To demonstrate that the decrease in EGFP ex-
pression was not related to toxic or non-speciﬁc effects of the chito-
san itself, we performed mock transfections with naked chitosan
(M) and transfections using NT siRNA. As shown in Fig. 2C, the
mock transfections resulted in only a small decrease in EGFP expres-
sion, reaching a minimum of 87% when using LIN100. In contrast and
as noted earlier, the delivery of NT siRNAmediated an increased EGFP
expression for some chitosans. One example is shown from the sam-
ples of cells transfected with LIN250, which showed up to 140% EGFP
expression compared to the untreated cells.
Selected nanoparticles based on the fully de-N-acetylated linear
chitosans were further characterized by measuring their z-average
hydrodynamic diameters in MQ water. As shown in Table 2, the size
of the nanoparticles ranged from approximately 30 to 100 nm. The
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particles of low DPn and N/P ratios were in general smaller compared
to those of increasing DPn and N/P.
The minimum effective dose for the knockdown of EGFP in H1299
cells was determined using LIN200 to deliver different concentrations
of anti-EGFP siRNA at N/P 30, and its efﬁciency was compared to that
of RiM. Fig. 3A shows that both carriers resulted in a more than 90%
reduction in EGFP expression at siRNA concentrations of 45 nM. Addi-
tional increase of the concentration mediated only a marginal in-
crease in gene silencing but there was a further 5% decline in the
number of EGFP positive cells as it increased from 45 to 75 nM.
LIN200 and RiM showed similar knockdown efﬁciencies in the select-
ed range of concentrations. However, a higher increase in the EGFP
expression was observed when the commercial transfection reagent
delivered NT siRNA as compared to the chitosan.
3.2. Knockdown kinetics and the silencing of GAPDH in selected cell lines
In addition to EGFP, we also examined the knockdown of GAPDH,
an ubiquitously expressed endogenous gene chosen as a model for a
random target. GAPDH was targeted by anti-GAPDH siRNA using the
chitosan LIN200, and the knockdown efﬁciency was determined
from levels of GAPDH mRNA and protein activity 48 h after transfec-
tion. The results presented in Fig. 4A show that anti-GAPDH siRNA de-
livered by LIN200 reduced the mRNA amount and the protein activity
to 18 and 55%, respectively, as compared to the untreated cells. The
delivery efﬁciency of chitosan was comparable to that of RiM, show-
ing mRNA levels and protein activity of 15 and 40% compared to the
untreated cells, respectively. Neither the delivery of NT siRNA nor
the mock transfection with chitosan showed any signiﬁcant effect
on the levels of GAPDH mRNA or protein activity.
The kinetics of GAPDH knockdown presented in Fig. 4B shows
mRNA levels of 10% already one day after transfection compared to
cells transfected with NT siRNA. The mRNA levels remained very
low and increased to only 20% ﬁve days after transfection. The protein
activity of GAPDH in transfected cells decreased from 50% one day
after transfection to 15% at day ﬁve, compared to cells treated with
NT siRNA. Cells transfected with NT siRNA were used as a negative
control rather than untreated cells because of observed differences
in the conﬂuencies between nanoparticle treated and untreated
cells. The cell density can affect the expression of GAPDH relative to
β-actin [25], and, consequently, samples of similar density were
compared.
Based on the encouraging results that show efﬁcient gene silenc-
ing in H1299 cells with e.g. LIN200 and LIN300, these chitosans
were applied to deliver siRNA in other cell lines. In this experiment,
the chitosans delivered anti-GAPDH siRNA and silenced the GAPDH
gene in MCF-7 cells and the primary cell line HUVEC. As shown in
Table 2
Z-average hydrodynamic diameter of nanoparticles based on fully de-N-acetylated lin-
ear chitosans with DPn 50-300 at N/P 10–60. Data represent mean values±s.d., n=3.
Hydrodynamic diameter
(z-average±s.d., nm)
N/P 10 30 60
LIN50 34.0±0.5 51.7±1.2 63.6±1.1
LIN100 45.3±7.1 48.1±1.6 61.9±1.2
LIN200 51.3±1.1 55.7±1.2 95.4±3.0
LIN300 57.9±5.7 58.4±4.2 89.3±8.6
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Fig. 5A and B, the nanoparticles successfully reduced GAPDH protein
activity in these cell lines, resulting in knockdown efﬁciencies of
~50–60% activity compared to the untreated cells 48 h after transfec-
tion, which is comparable to the results achieved in the H1299 cells.
Off-target or toxic effects were generally insigniﬁcant when NT
siRNA was delivered, but some reduction in GAPDH activity was ob-
served at N/P 30.
3.3. Toxicity
To determine the safety of the chitosan based nanoparticles used
in this study for delivering siRNA, the relative metabolic activity of
transfected cells was measured using the Alamar blue assay 4- and
48-h after transfection. As shown in Fig. 6A, a low but signiﬁcant de-
crease in metabolic activity was recorded in cells treated with a vari-
ety of formulations, both 4- and 48-h after transfection, compared to
the untreated cells. In general, the decrease was low, typically 5–10%.
Whereas only RiM and LIN300 at N/P 10 and 60 showed a signiﬁcant
decrease at 4 h, most chitosan nanoparticles with N/P 60 and RiM
were shown to decrease the metabolic activity 48 h after transfection.
In addition to the metabolic activity, cellular membrane integrity
was measured using the LDH cytotoxicity assay. Fig. 6B shows that
only cells treated with RiM suffered a signiﬁcant increase in leakage
of cytoplasmic LDH 48 h after transfection.
4. Discussion
This study demonstrates that fully de-N-acetylated chitosans with
moderate chain lengths are highly efﬁcient as siRNA carriers. The
maximum charge density obtained by complete de-N-acetylation ap-
pears crucial to obtaining high knockdown efﬁciencies (Fig. 1C). Par-
tially N-acetylated chitosan (FA0.15) and the AAM-substituted
SBTCO150 that contains uncharged N-acetylated glucosamine units
(GlcNAc) show signiﬁcantly lower knockdown compared to their
fully de-N-acetylated counterparts represented by LIN150 and
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SB150. The complete de-N-acetylation of chitosan thus eliminates the
need for ionic crosslinking of the nanoparticles and for trimethylation
of the amino groups.
Surprisingly, despite lower knockdown efﬁciencies, SBTCO150 and
FA0.15 show higher cellular uptake of siRNA (Fig. 1A). This observa-
tion indicates that these chitosans are able to form stable nanoparti-
cles with siRNA that are internalized, but their cellular processing
seems less efﬁcient than that for the linear or self-branched chitosans.
It is not clear why the increased uptake does not correlate with high
knockdown efﬁciency. Possibly, the acetylated chitosans release
siRNA in the endo-lysosomal compartments, as reported for
chitosan-mediated pDNA delivery by Thibault et al. [26], which re-
sults in rapid degradation. The lower charge density of these chito-
sans may also render them to be less efﬁcient in escaping the
endocytotic vesicles. The relationship between charge density, nano-
particle stability and silencing efﬁciency has previously been shown
to be positively correlated when assembling nanoparticles of chitosan
and siRNA at different DPn, FA or N/P ratios [13,17,21,27]. However,
the correlation between the uptake of nanoparticles and knockdown
was not investigated in these previous studies.
The siRNA delivery appears relatively unaffected by the chitosan
chain length, particularly for chitosans equal to and above DPn 100
(Fig. 2). This observation is in contrast to previous work on chitosan
mediated pDNA delivery, where the efﬁciency of gene transfer has
shown a critical dependency on chitosan chain length. It has been
shown that there is a balance between the nanoparticle stability
and its ability to undergo intracellular dissociation; the kinetics of
the intracellular dissociation can be optimized by selecting the proper
chain lengths [19]. Since the length of pDNA (typically several kbp)
largely exceeds that of siRNA, pDNA molecules are able to form mul-
tiple inter-chain bridges with chitosan molecules, and the electrostat-
ic interactions between pDNA and chitosan are thus much stronger.
Therefore, by using short chitosan chains (low DPn), the interaction
strength between pDNA and chitosan may be reduced, promoting in-
tracellular dissociation. Short siRNA duplexes, on the other hand, will
have substantially weaker interaction with chitosan, and this limits
the stability of the nanoparticles. Therefore, above a certain DPn, the
stability of the nanoparticles will not depend on the chitosan chain
length. This is in agreement with our data, showing that chitosans
below DPn 100 mediate weak siRNA uptake and knockdown, proba-
bly due to insufﬁcient stability of the nanoparticles. This is also in
agreement with results reported by Liu et al. [13], where a chitosan
of approximately DPn 50 and FA 0.05 has been shown to form unstable
nanoparticles at N/P 50 and to mediate poor knockdown [13]. How-
ever, as all chitosan preparations in this study are polydisperse with
respect to chain length, it is not possible to identify what would be
a minimum chain length for efﬁcient delivery.
When compared to other studies [13,17,21,28], our chitosan nano-
particles reach maximum knockdown efﬁciency at relatively low N/P
ratios such as an N/P of 10. Only the knockdown efﬁciency of LIN50,
and partially LIN100, increased with the N/P ratio (Fig. 2), suggesting
that a part of the chains in the polydisperse sample with average DPn
50 is able to form stable complexes with siRNA. The possibility of
compensating for the lower DPn of chitosans by increasing their N/P
ratios is generally not considered an optimal strategy, as higher N/P
ratios imply a large excess of free chitosans that bind to the cell sur-
face [8] and increase the potential for unspeciﬁc interactions. There-
fore, chitosan nanoparticles with low N/P ratios are highly
beneﬁcial. A plausible explanation for the low N/P ratios needed is
that the fully de-N-acetylated chitosans are able to bind siRNA more
tightly, thereby reducing the need for excess chitosan.
A signiﬁcant knockdown of the target gene was achieved at a
siRNA concentration as low as 15 nM, and the maximum gene knock-
down was reached at 45 nM (Fig. 3). Compared to other studies on
polycation-mediated siRNA delivery, concentrations in the range of
50–200 nM have been typically used to obtain efﬁcient gene
silencing, with the majority of studies in the upper concentration
range of 100–200 nM [17,21,28-31].
The siRNA-chitosan nanoparticles are also able to silence endoge-
nously expressed genes such as GAPDH. Despite low levels of GAPDH
mRNA that were already present at 24 h post-transfection and for up
to the ﬁve days measured (Fig. 4), the protein activity measured at
48 h remained between 30–55% of the control (Fig. 4A and B). This
range is signiﬁcantly higher than that observed when silencing the
EGFP gene and can be explained by the longer half-life of the
GAPDH (>35 h [32]) compared to the destabilized EGFP (2 h [33])
protein. Indeed, the GAPDH activity decreased further, reaching
below 20% at day 4–5, similar to the knockdown of EGFP at day 2
(Fig. 4B). Also, the EGFP knockdown kinetics was found to be similar
to the kinetics for the GAPDH mRNA (t1/2, GAPDH mRNA=8 h [34]), in-
dicating that the differences were caused by the different protein
turn-overs (data not shown).
It is well established that the ability of different carriers to deliver
siRNA is highly cell line dependent. After the successful delivery of
siRNA into HEK293, HeLa and H1299 (data shown only for H1299),
we also investigated delivery to primary cells (HUVEC) and MCF-7
cells that have previously proved difﬁcult to transfect. The knock-
down efﬁciencies obtained in these cell lines were similar to the
H1299 cells, further demonstrating that the chitosans used in this
study could be used as efﬁcient delivery vehicles for siRNA in a
broad range of cell lines.
The off-target effects of siRNA, the toxicity of the carrier and other
non-speciﬁc effects have repeatedly been lifted as serious concerns in
the ﬁeld of siRNA delivery [35–37]. Therefore, in all of our experi-
ments, appropriate non-targeting siRNA have been used as a negative
control to distinguish non-sequence speciﬁc effects. We also per-
formed mock transfection with chitosan only. As shown in Figs. 1C,
2C, and 3A, the delivery of NT siRNA in some cases increased the cel-
lular levels of EGFP whereas the naked chitosan in mock transfections
mediated only a moderate decrease in EGFP of ~10%. In contrast to
EGFP, the levels of GAPDH mRNA or protein activity do not seem to
be affected by the delivery of NT siRNA or the mock transfection
(Figs. 4A and 5), suggesting that the off-target effects inﬂuence ran-
dom genes and not the global gene expression in treated cells. The ex-
tent of increased EGFP seems to be more pronounced for chitosans of
mid-range DPn (Fig. 2C). Interestingly, mock transfections performed
at increased chitosan concentrations of 3.5, 35 and 70 μg/mL (corre-
sponding to N/P 10, 100, and 200) in a time course of 1–3 days
show 75–100% EGFP compared to the untreated cells. However, the
decrease seems to be random with respect to the chain length, the
time point and the chitosan concentration (data not shown).
The chitosan nanoparticles used in our study showed minimal cy-
totoxicity, as assessed by the analysis of metabolic activity and mem-
brane integrity (Fig. 6). Our results also emphasize the need to
evaluate several cellular parameters to determine the potential cyto-
toxicity of a compound [38]. Whereas RiM appeared to disrupt the
cellular membrane, hence causing leakage of cytoplasmic LDH, only
a low reduction of metabolic activity was observed. The low toxicity
of chitosan is in agreement with previous studies that recognize dif-
ferent types of siRNA- or pDNA-chitosan nanoparticles as safe deliv-
ery reagents [8–10,28,29,39]. However, Liu et al. [13] have shown
signiﬁcantly reduced metabolic activity when treating H1299 cells
with siRNA-chitosan nanoparticles, likely caused by the high siRNA
concentration and the N/P ratio in the formulation used. This result
highlights the importance of using tailored chitosans that are able
to deliver small doses of siRNA at low N/P ratios.
5. Conclusions
This study demonstrates that the choice of chitosan molecular
structure has a large impact on siRNA delivery and knockdown efﬁ-
ciency. Fully de-N-acetylated chitosans are superior siRNA carriers
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compared to conventional partially N-acetylated chitosans. These
chitosans demonstrate highly efﬁcient siRNA delivery in several cell
lines, potent long-term silencing of both exogenous and endogenous
target genes, low cytotoxicity, and few non-speciﬁc effects.
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